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ABSTRACT
IL-10 Gene Therapy for the Treatment of Pulmonary Inflammation
Sujatha Dokka
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that plays an important
regulatory role in inflammatory diseases. The overall goal of this research is to investigate
the potential therapeutic effect of IL-10 gene therapy for the treatment of pulmonary
inflammation and to develop appropriate gene delivery and expression systems for efficient
gene transfer to the lung. We evaluated various liposomal and non-liposomal agents
including LipofectAMINE®, Lipofectin®, DOTAP, DEAE-dextran, and the DNA condensing
agent protamine sulfate for their ability to promote gene transfection in macrophages. We
have developed an efficient transfection protocol which is at least 20-25 fold superior to
frequently used protocols for macrophage transfection. However, gene transfection in
macrophages is still low. Since macrophages are known to be highly susceptible to
endotoxin stimulation and endotoxin is a major contaminant of plasmid DNA preparations
used in most transfection studies, we investigated the effect of endotoxin on gene transfer
and the role of reactive oxygen species (ROS) in the process. Our results indicate that this
decreased transfection was dependent on ROS-mediated cellular toxicity induced by
endotoxin and that .OH radicals play a major role in this process. The mechanism of anti-
inflammatory action of IL-10 is incompletely understood. The present study also investigates
the possible role of ROS in NF-κB activation and IκBα degradation and their inhibition by IL-
10 in macrophages. Addition of IL-10 inhibited both IκBα degradation and generation of .OH
radicals in response to LPS stimulation.  These results provide, for the first time, direct
evidence for the role of IL-10 in ROS-dependent NF-κB activation. The next step was to
develop a protocol for in vivo gene transfer. Cationic liposomes represent a class of nonviral
vectors that hold great promise as gene delivery vehicles.  However, recent studies have
shown that they may be associated with some toxicity. We tested the hypothesis that the
positive charge of liposomes is a key determinant of toxicity. ROS play a key role in cationic
lipid-mediated toxicity. Finally, we established an efficient gene transfer protocol that results
in clinically relevant concentrations of IL-10 protein that can downregulate mouse lung
inflammation in response to LPS stimulation.
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OVERVIEW
Recent advances in molecular and cellular biology have identified the cellular
mediators that regulate many disease processes. One such mediator, Interleukin-10 (IL-10),
has been identified as an important negotiator between the immune and inflammatory
systems (de Vries, 1995; Moore et al., 1993). IL-10 is an anti-inflammatory cytokine that is
regularly produced during inflammatory processes in vivo, usually by the same cells (e.g.,
monocytes, T cells) that release inflammatory mediators. It inhibits the production of
inflammatory cytokines such as IL-1, IL-6, and tumor necrosis factor (TNF-α) by
macrophages stimulated with lipopolysaccharide (LPS) and interferon. The overall goal of
this study is to investigate the regulatory effect of IL-10 and to employ gene strategies to
deliver IL-10 in vivo.
Development of Efficient IL-10 Expression Vectors
Protein expression is a multi-step process. One key step is the transcription of the
corresponding gene in the nucleus. Although many vectors are efficient in delivering DNA
into the cytoplasm of cells, expression of the DNA is still hindered by inefficient transport of
DNA into the nucleus where the transcription machinery resides. Less than 1% of the DNA
enters the nucleus and is transcribed (Capecchi, 1980), leaving a significant amount of DNA
untranscribed in the cytoplasm. Cytoplasmic gene expression systems have been
developed to overcome this obstacle (Brisson et al., 1999; Gao and Huang, 1991). The
advantage of cytoplasmic systems is the capacity to induce gene transcription and protein
expression in the cytoplasm, thereby circumventing the problem of inefficient nuclear entry.
The goal of this study (Section I) is to construct and evaluate cytoplasmic and
nuclear vectors containing IL-10 gene, for their ability to express IL-10 protein.
Gene Transfection In Macrophages
Altered cytokine expression in macrophages has been implicated in a number of
pathologic disorders such as endotoxemia and sepsis. Hence, macrophages have been
identified as a key target for pharmacologic intervention via plasmid mediated gene transfer.
Our results show that macrophages are difficult to transfect relative to other cell types, and
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therefore there is a need for an efficient delivery system.  The purpose of this study (Section
II) was to develop a safe, noninvasive, and reproducible delivery system for macrophages.
A number of non-viral gene transfer methods have been developed to improve
transfection (Burkholder et al., 1993; Economou et al., 1989; Mack et al., 1998; Roussel et
al., 1988). However, these methods are associated with low transfection efficiency or high
cellular toxicity. The DEAE-dextran method of transfection is a well-established protocol that
has been shown to be superior to most other methods of transfection for macrophages
(Mack et al., 1998). To develop an efficient gene delivery system for macrophages, we
evaluated various liposomal and non-liposomal agents including LipofectAMINE®,
Lipofectin®, DOTAP, DEAE-dextran, and the DNA condensing agent protamine sulfate for
their ability to promote gene transfection.
Decreased Transfection in Macrophages: A Role for Endotoxin?
Over the years, numerous efforts have been made to improve gene transfection of
macrophages, however their transfection is still poor. The lack of understanding of the
causes that contribute to the refractory nature of macrophages during gene transfection is
partly responsible for this limited success.  Since macrophages are known to be highly
susceptible to endotoxin stimulation and endotoxin is a major contaminant of plasmid DNA
preparations used in most transfection studies, we hypothesized that the presence of
contaminating endotoxin may contribute to this low transfection.
Endotoxin is known to activate macrophages and induce the production of various
cellular mediators including reactive oxygen species (ROS) (Guthrie et al., 1984; Raetz,
1990). Transfection was greately reduced in macrophages in the presence of endotoxins.
Decreased transfection also correlated with increased cellular toxicity. Our hypothesis was
further confirmed by the fact that neutralizing the endotoxin, reversed LPS-induced cellular
toxicity and increased transfection.
Since ROS have been implicated in a variety of pathological processes and LPS is
known to stimulate ROS production in macrophages (Guthrie et al., 1984), we examined the
effect of different ROS scavengers on LPS induced cellular toxicity and decreased gene
transfection. Supporting our hypothesis, ROS scavengers decreased cellular toxicity and
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increased gene transfection in LPS induced macrophages. By choosing specific ROS
scavengers, we were also able to identify that hydroxyl radicals (.OH) maybe the principal
oxidative species responsible for the observed effects induced by LPS. Our ESR data also
confirmed that .OH radicals were indeed formed.
This is the first study reporting the role of ROS in causing decreased transfection in
macrophages.
Role of IL-10 as an Anti-Inflammatory Molecule in the Signal Transduction Pathway
Triggered by Endotoxin in Macrophages
While the role of IL-10 as an anti-inflammatory molecule has been well established,
the mechanism by which it exerts its action is still not well understood and the experimental
results are controversial. Macrophages are known to generate reactive oxygen species
(ROS) in response to stimuli (Rojanasakul et al., 1993). Because ROS have been implicated
as the common messenger involved in NF-κB activation by diverse stimuli (Baeuerle and
Henkel, 1994), we hypothesized that IL-10 may exert its effect on NF-κB activation by
changing the redox status of stimulated cells through an ROS-dependent pathway.
The results of our study (Section IV) show that ROS are involved in the signal
transduction pathway leading to NF-κB activation and IκBα degradation. The data from ESR
studies shows that IL-10 inhibits LPS-induced .OH production. Based on these results we
proposed a mechanism of action of IL-10 which involved the modulation of ROS production.
This study provides a new insight into the mechanism of the inhibitory effects of IL-
10.
Cationic Liposomes as Non-Viral Gene Delivery Systems In Vivo
After the role of IL-10 as an anti-inflammatory cytokine was established, the next
step was to develop an efficient gene transfer protocol for IL-10 gene therapy. Cationic lipids
represent a class of non-viral vectors that have been used successfully in both in vitro (Behr
et al., 1989; Felgner and Holm, 1989; Gao and Huang, 1991) and in vivo (Brigham et al.,
1989; Lee et al., 1996) gene transfer. Since we established a gene transfer protocol for
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macrophages in vitro, we tested the same system in vivo. The polyvalent cationic liposome,
LipofectAMINE, which was efficient and non-toxic in vitro, was found to be very toxic in vivo.
The origin of toxicity caused by cationic liposomes is not well understood. We
hypothesized that the positive charge of liposomes plays an important role in lung toxicity.
To test this hypothesis, we instilled differently charged liposomes into mice lungs and tried
to elucidate the mechanism of pulmonary toxicity (Section V). The results from this study
show that positively charged liposomes caused an increase in the number of inflammatory
cells in the lung which are responsible for the release of inflammatory mediators such as
cytokines and ROS. To confirm that ROS are responsible for the toxicity observed, mice
were pretreated with ROS scavenger, PBN. Pretreatment with PBN decreased cationic
liposome-mediated inflammation and toxicity.
We report in this study, for the first time, the role of ROS in cationic lipid-mediated
toxicity. The results of this study have great significance in the development of cationic lipid-
based gene delivery systems.
IL-10 Gene Therapy for the Treatment of Lung Inflammation
Our final and ultimate goal was to evaluate the therapeutic potential of IL-10 gene
therapy for the treatment of lung inflammation. Most studies to date have used recombinant
IL-10 protein (Howard et al., 1993; Kuhn et al., 1993). Recombinant protein has the
disadvantage of being short-lived and expensive. Gene therapy, on the other hand, offers a
cheaper more economical alternative and has the additional advantage of a possible
prolonged expression. To study the effect of IL-10 gene therapy, we utilized a murine lung
inflammation model. IL-10 plasmid delivery was optimized using a monovalent cationic
liposome, DOTAP. We report here, for the first time, that intratracheal administration of
pDNA/cationic liposome complexes results in clinically relevant concentrations of IL-10
protein. This IL-10 gene transfer can downregulate mouse lung inflammation and cell
activation in response to LPS stimulation. The results of this study are very significant
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SPECIFIC AIMS
1. To construct different cytoplasmic and nuclear expression vectors containing IL-
10 gene and to select the best expression vector for subsequent gene transfer
studies (Section I).
Our first goal was to develop IL-10 expression vectors capable of expressing high
levels of IL-10 protein. The potential advantages of cytoplasmic systems are higher
and faster expression of gene than that of the nuclear expression system because
the messenger transcribed from the cytoplasmic vector can be immediately
translated into the cytoplasm. Two IL-10 expression vectors, cytoplasmic (T7
promoter driven) and nuclear (CMV promoter driven), were constructed. These
plasmid vectors were transfected into macrophages and IL-10 expression was
measured and compared.
2. To develop an efficient gene delivery system for macrophages (Section II).
A number of commercially available liposomal agents and DEAE-Dextran were
tested for their transfection efficiency. CMV-luciferase and CMV-β-gal were chosen
for all optimization studies. Luciferse and β-gal assays were used to quantitate gene
expression and LDH assay was used to measure toxicity. Gene transfection studies
were performed in various cell lines including RAW 264.7, 293, HepG2 and A549.
3. To investigate the effect of endotoxin on gene transfection efficiency and the role
of reactive oxygen species in this process (Section III).
To investigate the cause of decreased transfection in macrophages, the effect of
contaminating endotoxin in plasmid DNA preparations was studied. LDH activity was
used as an indicator for cellular toxicity, and ESR was employed to study ROS
generation induced by endotoxin. To confirm the role of ROS in gene transfection,
ROS scavengers including PBN, catalase, superoxide dismutase and sodium
formate were added to the transfection medium and cellular toxicity and gene
expression were measured.
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4. To investigate the possible role of ROS and their inhibition by IL-10 in NF-κB
activation and IκBα degradation in macrophages (Section IV).
The mechanism by which IL-10 exerts its anti-inflammatory effect is not completely
understood. Hence, we studied the effect of IL-10 on different steps of the signal
transduction pathway in stimulated macrophages. ELISA was employed to measure
cytokine IL-10 and TNF-α levels. Gel-Shift assay was used to study NF-κB-DNA
binding activity and Western Blot was used to measure IκBα degradation. A stable
cell line expressing IL-10 was generated to aid mechanistic studies. ESR studies
were carried out to study free radical generation and IL-10 inhibition. Specific ROS
scavengers were used to determine the key species involved in the signal
transduction process.
5. To study the toxicity associated with polycationic liposomes and to elucidate the
underlying mechanism of pulmonary toxicity of polycationic liposomes in vivo
(Section V).
The potential utility of any delivery system depends on its safety. The observation
that the cationic liposome, LipofectAMINE, was very toxic in vivo, led to further
studies into the mechanism of toxicity of cationic liposomes. To test the hypothesis
that the positive charge of liposomes is responsible for toxicity, we tested the effect
of intratracheal instillation of differently charged liposomes. Intratracheal
administration of liposomes facilitated delivery to the lung. Polymorphonuclear (PMN)
cell counts and LDH assays were performed on the bronchoalveolar lavage fluid
(BALF). Free radical production was assessed by luminol-dependent
chemiluminescence. To confirm the role of ROS in the development of pulmonary
inflammation and toxicity, mice were preinstilled with ROS scavenger before LPS
stimulation.
6. To develop an efficient gene transfer protocol for IL-10 in vivo and to study the
therapeutic potential of IL-10 in the treatment of lung inflammation (Section VI).
The final goal of this study was to determine the therapeutic potential of IL-10 in
pulmonary inflammation. A lung inflammation model was developed by instilling LPS
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intratracheally into mice. Since naked DNA is not efficiently expressed in our system,
it was necessary to develop a delivery system. DOTAP, a monovalently charged
cationic liposome, was chosen because of its relatively non-toxic nature (Section V).
The ratio of pDNA:DOTAP was varied and the expression of IL-10 was measured in
the BALF by ELISA. The IL-10 expression was also measured at different time
intervals after gene delivery to determine the time point at which expression is at the
maximum. Finally, to study the therapeutic potential of IL-10 gene therapy, mice
were preinstilled with the IL-10 gene delivery system before inducing lung
inflammation with endotoxin. Lung inflammation was analyzed by PMN counts and
TNF-α levels in the BALF.
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SECTION I
Development of Efficient IL-10 Expression Vectors
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I.1. ABSTRACT
Protein expression is a multi-step process. One key step is the transcription of the
corresponding gene in the nucleus. Several gene delivery systems have been developed to
introduce functional genes to the cell nucleus in order to induce therapeutic protein
expression. However, nuclear entry of exogenously administered genes is inefficient and
often results in poor protein expression. The present study investigates the feasibility of
utilizing a cytoplasmic gene expression system to induce gene transcription and protein
expression in the cytoplasm, thereby circumventing the problem of nuclear entry. This
expression system entails genes driven by the bacteriophage T7 promoter to be expressed
in the cytoplasm when co-delivered with T7 RNA polymerase. The overall goal of this study
is to develop a gene transfer protocol for efficient expression of IL-10 protein in
macrophages. To this end, we have generated both cytoplasmic and nuclear IL-10
expression vectors. RAW 264.7 cells were transfected with both cytoplasmic and nuclear
vectors using cationic liposomes. Our results show that the nuclear expression system was
approximately 14 fold more effective than the cytoplasmic system in expressing IL-10




One of the principal barriers to effective gene therapy is the development of efficient
vectors that can deliver therapeutic gene to its target site, i.e., the nucleus. Viral vectors
have achieved best results so far. However, the safety concerns and the immunological
profile of viral vectors have steered research towards the development of efficient non-viral
carriers (Roth and Cristiano, 1997). Non-viral gene delivery systems are limited by their low
transfection efficiency (Ledley, 1995). Nuclear trafficking of plasmid DNA has been identified
as one of the major hurdles to efficient transfection (Capecchi, 1980; Zabner et al., 1995).
Although many vectors are efficient in delivering DNA into the cytoplasm of cells,
expression of the DNA is still hindered by inefficient transport of DNA into the nucleus where
the transcription machinery resides (Fig. 1) (Capecchi, 1980). To overcome this obstacle, a
cytoplasmic expression system has been developed by utilizing a reporter gene driven by a
bacteriophage T7 promoter (Gao and Huang, 1993). Expression of this gene is dependent
on the codelivery of T7 RNA polymerase, which remains largely in the cytoplasm due to the
lack of a nuclear localization signal in the molecule (Dunn et al., 1988). In this system, the
T7 RNA polymerase can drive the expression of a reporter gene (e.g., pT7-CAT) in the
cytoplasm (Fig. 2). Thus, cytoplasmic expression systems bypass the need for the DNA to
enter the nucleus, which has been identified as the rate-limiting step for efficient DNA
delivery. However, the disadvantages of this system are: 1) transient expression due to
rapid degradation or inactivation of the T7 RNA polymerase enzyme, 2) potentially
immunogenic because a foreign protein is being delivered, and 3) can be very expensive
especially in vivo.
To overcome these problems, Brisson et al. (Brisson et al., 1999) developed a new
T7 RNA polymerase expressing vector pCMV/T7-T7pol consisting of the T7 RNA
polymerase gene driven by both a human CMV promoter and a bacteriophage T7 promoter.
pCMV/T7-T7pol does not require exogenous T7 RNA polymerase to initiate the
transcription. Once pCMV/T7pol enters the cell through endocytosis, some of the DNA is
released into the cytoplasm (Fig. 3). A portion of pCMV/T7-T7pol undergoes nuclear
transport where transcription is initiated at the CMV promoter. The pCMV/T7-T7pol mRNA
would then be transported into the cytoplasm for translation into T7 RNA polymerase
protein. This newly synthesized protein could then recognize the T7 promoter located on
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pCMV/T7-T7pol and begin transcription in the cytoplasm through a possible autoregulatory
mechanism (i.e autogene mechanism). Therefore, pCMV/T7-T7pol could continuously
supply the cell with a source of T7 RNA polymerase to transcribe target genes containing a
T7 promoter in the cytoplasm (Fig. 3).
Since pCMV/T7-T7pol takes advantage of the large amounts of DNA that remain in
the cytoplasm after transfection, theoretically this system should be more efficient in
expressing delivered genes than a nuclear expression system. Thus, the potential
advantages of cytoplasmic systems are higher and faster expression of gene compared to
that of the nuclear expression system because the messenger transcribed from the T7
vector can be immediately translated in to the cytoplasm.
The goal of this study is to develop an expression vector that would result in
maximum expression of IL-10 protein. To this end we constructed both cytoplasmic and
nuclear vectors expressing IL-10. The expression of both vectors was measured in the
macrophage cell line RAW-264.7 and the best vector was chosen for all further experiments.
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I. 3. MATERIALS AND METHODS
Plasmids
Plasmid pT7-CAT, a plasmid containing the CAT reporter gene driven by the
bacteriophage T7 promoter (Elroy-Stein and Moss, 1990), was a kind gift provided by Dr. L.
Huang (University of Pittsburgh). pCMV-IL10 used for nuclear expression of the IL-10 gene
driven by the human cytomegalovirus immediate early promoter (CMV) was a kind gift
provided by Dr. H. Tahara (University of Pittsburgh). PCMV/T7-T7pol was constructed as an
expression plasmid for T7 RNA polymerase gene driven by its cognate T7 promoter and the
human CMV promoter (Brisson et al., 1999). A HindIII/BamHI fragment from pAR3126
(Dunn et al., 1988) containing the cDNA of T7 RNA polymerase was inserted into the
corresponding sites of the pcDNA3 plasmid vector (Invitrogen Corp., San Diego, CA) to
generate pCMV/T7-T7pol (Brisson et al., 1999). This vector was amplified in E. Coli DH5α
cells and purified using Qiagen Plasmid Maxi Kits. Plasmid pT7-mIL10, which contains an
IL-10 gene driven by a T7 promoter was made in our lab by inserting a mIL-10 fragment into
the plasmid pT7-CAT after deletion of the cDNA encoding CAT gene. pT7-CAT plasmid was
first treated with BamHI/NcoI restriction enzymes that specifically cut out the fragment
responsible for CAT expression. A BamHI/NcoI fragment from another plasmid containing
mIL-10 gene was inserted into the corresponding sites of the cut pT7-vector (the new vector
was designed pT7-mIL10). This vector was amplified in E. Coli DH5α cells and purified
using Qiagen Plasmid Maxi Kits (Qiagen, Chalsworth, CA).
Cell Culture
The macrophage cell line RAW 264.7 was obtained from the American Type Cell
Culture Collection (Rockville, MD).  The cells were grown in DMEM supplemented with 10%
fetal bovine serum (FBS), 2 mM L-glutamine, and 100 U/ml penicillin-streptomycin.  They
were maintained at 37oC in a humidified atmosphere containing 5% CO2.  Prior to use, cells
were briefly trypsinized or mechanically scraped and centrifuged.  They were plated at
~1x106 cells/ml in 12-well tissue culture plates one day before transfection studies.
Transfections
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For transfection of cytoplasmid vector, 0.3 µg of pCMV/T7-T7pol per µg pT7-mIL10
were first diluted in serum-free medium before complexing with DC-Chol:DOPE liposomes
(10 nmol lipid/µg DNA). These mixtures were used to transfect cells for 4 h at 37oC after
which transfection medium was replaced with growth medium. Cells were incubated for an
additional 2 days at 37oC following transfection before cell supernatants were assayed for
the cytokine IL-10 level. For pCMV-mIL10, 1 µg DNA was complexed with DC-Chol:DOPE
liposomes (10 nmol lipid/µg DNA) for transfection. Toxicity was determined by comparing
the total protein remaining in each well following transfection with the total protein remaining
in untreated wells. Total protein was measured by Coomassie Plus Protein Assay Reagent
(Pierce, Rockford, IL).
Determination of IL-10 Protein Concentrations
Cell-free supernatants were collected 2 days post transfection and were assayed for
IL-10 protein by enzyme-linked immunosorbent assay (ELISA) kits specific for murine IL-10
and protein levels were measured as specified by the manufacturer (Endogen). The
sensitivity of the assays ranged from 15 to 31 pg/ml. The coefficient of variation for all
cytokine assays was <10%.
Restriction Digestion
The following mixture was prepared: DNA (0.5 µg), restriction buffer (10X, 1.5 µL),
BamHI (1 µl), NcoI (1µl) and distilled water q.s. to 15 µl. This mixture was incubated at 37oC
for 1 h. The enzymes were then inactivated by heating at 65oC for 10 min. The efficiency of
restriction digestion was then analyzed by running the incubation mixture on a 0.8% agarose
gel. Unless otherwise indicated, all enzymes used in this study were purchased from New
England Biolabs.
Isolation of DNA Fragments after Restriction Digestion
The desired fragments were purified from 0.8% agarose gels by following the
manufacturer’s instructions (GENECLEAN II Kit, BIO 101 Inc., La Jolla, CA). Briefly, the
desired band was excised from the agarose gel. Three volumes of NaI stock solution was
added and was incubated at 450-550C for 5 min to dissolve agarose. GLASSMILK
suspension from the GENECLEAN II Kit was added and this mixture was incubated for 5
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min. The GLASSMILK/DNA complex was pelleted for 5 sec. This pellet was washed 3 times
with NEW WASH buffer. The DNA was then eluted into water or low-salt buffer.
Ligation of DNA Fragments
The following mixture: DNA fragment to be inserted (mIL-10, 50 ng), Cut Vector
(pT7, 50 ng), Ligase Reaction Buffer (5X, 2 µl), T4 ligase (1 µl), and distilled water q.s. 10 µl,
was incubated at 160C overnight.
Transformation
Five microliters of ligation mixture were added to 20 µl of DH5α competent cells (Life
Technologies), and this mixture was incubated for 30 min on ice. The tubes were then
placed at 370C for 1 min and then immediately put on ice for 2 min. One half milliliter of LB
Broth was then added to the mixture and this mixture was incubated at 370C with shaking for
1-2 h. Cells were then plated on ampicillin-agar plates and incubated overnight at 370C.
Selection of Positive Colonies
After transformation, a few colonies were picked and amplified in LB Broth containing
ampicillin. Cells were then lyzed and miniprep was performed according to the protocol
described in Sambrook et al. (Sambrook et al., 1989). After purification of DNA, restriction
digestion was performed using BamHI and NcoI restriction enzymes. The digested mixture
was then analyzed by running a 0.8% agarose gels. The colonies that exhibited the
expected fragmentation pattern were then selected. DNA was extracted from these colonies
and was then sent for DNA sequencing using the right primers. Sequencing data is the final




Fig. 4 (A, B) shows the steps involved in the construction of plasmid pT7-mIL10.
First, mIL10 fragment was cut from the plasmid CMV-mIL10 using BamHI/NcoI restriction
enzymes. Similarly, another plasmid, pT7-CAT, was cut using BamHI/NcoI. The restriction
digestion mixture was then run on a 0.8% agarose gel. Fig. 4C shows agarose gel analysis
after restriction digestion of both plasmids. The larger T7 fragment and the smaller mIL10
fragment were then purified from the cut gel using GENECLEAN as discussed in the
Methods section. Equal concentrations of vector and fragment were then ligated at 160C
overnight. The next step was transformation into DH5α competent cells and finally few
colonies were selected. Miniprep was performed on each of these colonies to isolate DNA.
The DNA was then subject to restriction digestion by BamHI/NcoI and the fragmentation
pattern was analyzed by running 0.8% agarose gel. As shown in Fig. 4D, colony 6 had the
potential to be a positive colony because the two fragments generated on restriction
digestion had the expected molecular weights. This DNA was then sent for sequencing
analysis and was found to have the desired sequences. This step concluded the preparation
of plasmid pT7-mIL10.
Comparison between Cytoplasmic and Nuclear Systems
The goal here is to compare the cytoplasmic and nuclear systems and to choose the
best vector for all further studies. The ratio of autogene and liposomes per µg DNA has
been optimized previously (Brisson et al., 1999). RAW 264.7 macrophage cell line was
chosen because the overall goal of our project is to develop IL-10 gene transfer for
macrophages. Cytoplasmic vector pT7-mIL10 expressed IL-10 (3,600-4,737 pg/ml) (Fig. 5).
However, CMV-mIL10 expressed much more IL-10 protein (50,000-71,528 pg/ml). These
results suggest that transgene expression of the nuclear expression vector is more effective
than that of the cytoplasmic vector.
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I.5. DISCUSSION
Nuclear expression is the fundamental way in which proteins are expressed in cells.
DNA transported to the nucleus is transcribed into mRNA which is then translated into
protein in the cytoplasm. However, less than 1% of the DNA enters the nucleus (Capecchi,
1980) and is transcribed, leaving a significant amount of DNA untranscribed in the
cytoplasm. Cytoplasmic systems have been proposed as a means of bypassing the
requirement of the pDNA to enter the nucleus (Brisson et al., 1999a; Brisson et al., 1999b;
Chen et al., 1995; Deng and Wolff, 1994; Dubendorff and Studier, 1991; Dunn et al., 1988;
Elroy-Stein and Moss, 1990; Gao and Huang, 1993; Gao et al., 1994; Lieber et al., 1989).
The cytoplasmic expression system contains a reporter gene driven by the
bacteriophage T7 promoter and the purified T7 RNA polymerase (Gao and Huang, 1993).
T7 RNA polymerase was chosen because it does not enter the nucleus due to the lack of a
nuclear localization signal (Dunn et al., 1988). Recently, Brisson et al. (Brisson et al., 1999a)
developed a novel cytoplasmic expression vector, pCMV/T7-T7pol. pCMV/T7-T7pol consists
of a nuclear CMV promoter followed by a cytoplasmic T7 promoter and the T7 RNA
polymerase gene. RNA polymerase II begins transcription in the nucleus via the CMV
promoter on the autogene. T7 RNA polymerase is then translated in the cytoplasm. The T7
RNA polymerase produced will then begin transcription at the T7 promoter which induces T7
RNA polymerase transcription in the cytoplasm. Because of this autogene system, a
continuous amount of T7 RNA polymerase is provided to the cell to transcribe pT7-reporter
genes. This system obviates the need for delivering exogenous RNA polymerase which
could be potentially toxic and immunogenic. Using a reporter gene assay, Brisson et al.
(Brisson et al., 1999b) have shown that this cytoplasmic system is superior to nuclear
expression vector, pCMV-CAT.
The overall goal of this study is to develop an efficient gene transfer protocol for the
delivery of IL-10. Since, it has been claimed that cytoplasmic systems are better than
nuclear systems (Brisson et al., 1999b), we constructed both cytoplasmic and nuclear
vectors expressing IL-10 protein. Murine macrophages, RAW 264.7, were transfected with
both the expression vectors. In our system we found that while pT7-mIL10 vector does
express IL-10 protein, pCMV-mIL10 expresses IL-10 almost 14 times more.
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The discrepancy in the test results is not completely understood. However, a
difference between the study of Brisson et al. (1999b) and ours is the cell line used. They
used 293 cells which are kidney embryonic cells. It is possible that the T7 RNA polymerase
produced by the autogene system is degraded or inactivated to a greater extent in
macrophages due to their phagocytic activity. Macrophages are known to possess a high
level of digestive enzymes, especially in the endosomes and lysosomes. Since the DNA
complex enters the cells by endocytosis, it is likely that a substantial portion of the
internalized complex is degraded in the cells. It is beyond the scope of this study to
investigate the exact cause of this discrepancy. Our goal is to merely find the best available
expression system for subsequent studies. Since pCMV-mIL10 showed greater transgene
expression, this plasmid expression system was chosen for all further experiments.
- 20 -
I.6. FIGURES
Fig. 1. Poor Nuclear Delivery of DNA. There are a number of barriers for DNA delivery.
Even if the delivery system allows DNA to enter the cytoplasm, DNA has to still enter the
nucleus where transcription machinery resides. The transcription of transgene completely
depends on the activity of endogenous RNA polymerase (II or III) which resides in the







Fig. 2. T7 Cytoplasmic Expression System. This sytem relies on the ability of the
exogenously supplied T7 RNA polymerase to drive expression of transgene under the









Fig. 3. pCMV/T7-T7pol Autogene System. (1) pT7-CAT and autogene codelivered into the
cell (2) Some autogene enters the nucleus (3) it starts initial round of T7-RNA polymerase
expression (4) This T7-RNA polymerase can drive expression of T7-polymerase due to



















Fig. 4A.  General Steps Involved in Construction of Plasmids
Isolate T7-vector and mIL-10 fragments
Ligate fragments
Transformation
Miniprep to purify DNA
Restriction Digestion and Agarose Gel
Identify the positive colonies
Sequencing of DNA to select the positive colonies
Amplify and grow plasmid in large quantities
Plasmid ready to use
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Fig. 4B. Schematic of the Generation of pT7-mIL10. mIL10 fragment is cut and isolated
from a different vector and T7-vector is also digested with the same restriction enzymes.












Fig. 4C. Construction of pT7-mIL10 Plasmid. T7-CAT vector is cut with BamHI/NcoI and
the larger fragment (T7-vector) is separated. Similarly, mIL-10 fragment is isolated from




Fig. 4D. Construction of pT7-mIL10 Plasmid. After ligation of the two fragments and
transformation, few colonies are selected, DNA is isolated, and then restriction digestion is
performed to study the fragmentation pattern. Based on the gel analysis, colony 6 has the
desired fragmentation pattern because digestion with BamHI/NcoI gives 2 fragments which
correspond, in molecular weight, to the larger T7-vector and the smaller mIL10 fragments.
This colony was then selected, and DNA was sent for sequencing analysis to further confirm
that this is indeed the positive colony.   




Fig. 5. Comparison of Transgene Expression of Cytoplasmic and Nuclear Systems.
For transfection of cytoplasmic vector, cells (1x106/ml), were transfected for 4 h at 37oC with
0.3 µg of pCMV/T7-T7pol per 1 µg pT7-mIL10 in the presence of DC-Chol:DOPE liposomes
(10 nmol lipid/µg DNA). For pCMV-mIL10, 1 µg DNA was complexed with DC-Chol:DOPE
liposomes (10 nmol lipid/µg DNA) for transfection. As a control (CON), cells were
transfected with pCMV-control vector with DC-Chol:DOPE liposomes (10 nmol lipid/µg
DNA). Two days post-transfection, cell supernatants were assayed for cytokine IL-10 levels
as described in the Methods section.  Each data point represents the mean (with standard
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of Macrophages by Lipoplexes
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II.1. ABSTRACT
Macrophage transfection studies are crucial to understanding gene regulation and
expression.  However, gene transfection in macrophages is difficult.  We have shown here
that macrophages are more resistant to gene transfection compared to other cell types. To
further develop an efficient gene delivery system for macrophages, we evaluated various
liposomal and non-liposomal agents including LipofectAMINE®, Lipofectin®, DOTAP, DEAE-
dextran, and the DNA condensing agent protamine sulfate for their ability to promote gene
transfection.  CMV-luciferase was used as a reporter plasmid.  Macrophage transfection was
maximal at the DNA:LipofectAMINE:protamine ratio of 1:12:1 µg/ml.  The LipofectAMINE
formulation showed a 10-12-fold increase in transfection efficiency over DOTAP and a 4-5-
fold increase over Lipofectin.  This transfection method showed minimal toxicity at the
concentrations tested and was at least 20-25-fold superior to the most frequently used
DEAE-dextran method for macrophage transfection.
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II.2. INTRODUCTION
Macrophages play an important role in host defense against noxious substances and
are involved in a variety of disease processes including autoimmune diseases, infections
and inflammatory disorders (Pierce, 1990).  Molecular analysis of macrophage functions can
be accomplished by gene transfection assays.  However, gene transfection in macrophages
has proven difficult.  A number of non-viral gene transfer methods have been developed to
improve macrophage transfection, including calcium-phosphate precipitation (Roussel et al.,
1988; Stief et al., 1989), DEAE-dextran (Hess et al., 1985; Mack et al., 1998; Rupprecht and
Coleman, 1991), particle bombardment (Burkholder et al., 1993), and electroporation
(Daumler and Zimmermann, 1989; Economou et al., 1989).  These methods are however
associated with low transfection efficiency or high cellular toxicity.  Being non-dividing cells,
macrophages are also resistant to viral-mediated gene transfection, e.g. retroviruses.
Adenoviral vectors, although capable of transfecting non-dividing cells, are associated with
immunogenicity, and thus their use has been limited.
The DEAE-dextran method of transfection has been described as the most efficient
gene transfer method for macrophages developed thus far (Mack et al., 1998).  This method
was shown to be more efficient than other existing methods including the calcium
phosphate, electroporation and lipofection (Mack et al., 1998).  In our hand, this method
provides a reasonable but still relatively low transfection efficiency.  In this study, we further
developed gene transfection systems for macrophages using a variety of liposomal agents.
We optimized the transfection efficiency of these systems and compared them to the DEAE-
dextran method.  In addition, we tested the effect of protamine sulfate on liposome-mediated
gene transfer.  Protamine is a major component of sperm nucleus with a role in DNA
stabilization.  This compound has been shown to cause condensation of DNA which
promotes the cellular entry and gene expression of plasmid DNA (Sorgi et al., 1997).  Our
results showed that the optimized liposomal systems were more effective and less toxic than
the DEAE-dextran and that protamine greatly enhanced the level of transgene expression
mediated by liposomes.
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II.3. MATERIALS AND METHODS
Cell Culture
All cell lines including the macrophage RAW 264.7, alveolar epithelial A549, kidney
embryonic 293, and liver HEPG2 were obtained from the American Type Cell Culture
Collection (Rockville, MD).  The cells were grown in DMEM supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, and 100 U/ml penicillin-streptomycin.  They were
maintained at 37oC in a humidified atmosphere containing 5% CO2.  Prior to use, cells were
briefly trypsinized or mechanically scraped and centrifuged.  They were plated at ~1x106
cells/ml in 12-well tissue culture plates one day before transfection studies.
Plasmid DNA
The expression vector CMV-luciferase contains the promoter-enhancer region of
Cytomegalovirus upstream from the luciferase gene (kindly provided by Dr. Leaf Huang,
University of Pittsburgh). The expression vector CMV--gal contains the promoter-enhancer
region of Cytomegalo virus upstream from the -galactosidase gene (kindly provided by Dr.
Ye, NIOSH). The plasmid was purified using the Qiagen Endofree plasmid kit (Qiagen,
Chatsworth, CA) according to the manufacturer’s instructions.
Liposomal Transfection
Approximately 1x106 cells were plated on a 12-well plate and allowed to grow for 24
hours before the transfection.  The plasmid DNA (0.5-2 g) was diluted in 200 l of DMEM.
In some studies, the indicated amounts of protamine sulfate were added to the DNA.  The
liposome was diluted in 200 l of DMEM.  The diluted DNA and liposome were combined
and incubated at room temperature for 15-20 min.  Cells with transfection reagents were
incubated for 4 hours.  Transfection medium was then replaced with growth medium
containing 10% FBS.  Cells were cultured for an additional 48 hours before the level of gene
expression was determined.  All transfections were conducted under sterile conditions and
duplicate plates were tested for each condition.
DEAE-dextran Transfection
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Approximately 1x106 cells were plated on a 12-well plate and allowed to grow for 24
hours before the transfection.  The plasmid DNA (1 µg/ml) was mixed with varying
concentrations of diethylaminoethyl-dextran (0-200 µg/ml) (Sigma, St. Louis, MO) in DMEM.
The diluted DNA and DEAE-dextran were added to pre-washed cells.   Wrapped plates
were incubated at 37oC for 2 hours.  The cells were then washed and incubated with growth
medium containing 10% FBS.  The cells were cultured for an additional 48 hours before the
level of gene expression was determined.  All transfections were conducted under sterile
conditions and duplicate plates were tested for each condition.
Measurement of Luciferase Activity
Luciferase synthesized during the in vitro translation was quantitated by the assay of
enzyme-dependent light production using a luciferase assay kit (Promega, Madison, WI).
Cells were washed twice with PBS and incubated at room temperature for 10 min in the
presence of 250 µl of lysis buffer (Promega) and then centrifuged at 12000g.  Ten
microliters of each sample was placed in a 5-ml polystyrene test tube and the tubes were
then loaded into an automated luminometer (BioRad, Hercules, CA).  At the time of
measurement, 100 µl of luciferase substrate was automatically injected into each sample,
and total luminescence was measured over a 20-sec time interval.  Output is quantitated as
relative light units (RLU).  Protein concentration in the supernatant was determined by BCA
protein assay reagent (Pierce, Rockford, IL).  Luminescence detected was standardized per
µg protein present in the supernatant.
X-Gal Assay
Forty-eight hours after transfection, cells were washed, fixed with 1.8% formaldehyde
and 2% glutaraldehyde, and then incubated for 16-24 h at 37oC with 1 ml of 20 mg/ml X-gal
(5-bromo-4-chloro-3-indolyl-β-galactopyranoside) (Life Technologies) in dimethyl formamide




LDH assay was performed to assess the effect of test agents on cellular toxicity.
Cells were treated with plasmid DNA and transfecting agents, either individually or in
combination as indicated.  After the treatments, the cell supernatants were collected and
assayed for LDH activity.  LDH activity was determined by monitoring the oxidation of
pyruvate coupled with the reduction of NAD at 340 nm using an LDH assay kit (Roche
Diagnostic Systems, Montclair, NJ).  The assay was performed on Cobas Fara II Analyzer
(Roche Diagnostic Systems).  One unit per liter of LDH activity is defined as the amount of
enzyme that converts 1 µmol of lactate to 1 µmol of pyruvate with the concomitant reduction
of 1 µmol of NAD to 1 µmol of NADH per minute per liter of sample in the assay procedure.
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II.4. RESULTS AND DISCUSSION
Comparison of Gene Transfection in Different Cell Lines
Gene transfection is known to be cell type-dependent.  In our experience we found
that macrophages are difficult to transfect.  To substantiate this point, we carried out a
comparison study in which various cell lines from different origins including the macrophage
RAW 264.7, kidney embryonic 293, alveolar epithelial A549 and liver HEPG2 were
transfected with the CMV-luciferase reporter plasmid.  Gene transfection was carried out
under the same transfection conditions using LipofectAMINE as a transfecting agent.  Fig.
1A shows that all four cell lines were minimally transfected in the absence of liposome.  With
liposome, the transfection efficiency was greatly enhanced in all cell lines tested.  However,
the level of enhancement was most pronounced in the HEPG2 cells, followed by the
embryonic 293, epithelial A549, and macrophage RAW 264.7 cells, respectively.  Similar
results are seen with -gal reporter plasmid (Fig. 1B). These results supported previous
observations that different cell lines exhibit different levels of transfection and that
macrophages are relatively difficult to transfect compared to other cell types.  The basis for
the low transfection in macrophages is not known but probably due to the presence of high
enzymatic activities and the non-proliferating nature of this cell type. Macrophages are
scavenging cells possessing a high level of digestive enzymes which could inactivate DNA
and result in low transfection efficiency.
DEAE-Dextran and LipofectAMINE-Mediated Gene Transfer
To develop an efficient system for transfecting macrophages, we evaluated DEAE-
dextran and LipofectAMINE for their transfection efficiency.  The DEAE-dextran method of
transfection is a well-established protocol that has been shown to be superior to most other
methods of transfection for macrophages (Mack et al., 1998; Rupprecht and Coleman,
1991).  In the present study, we further tested DEAE-dextran in our system and compared
its transfection efficiency to that of the LipofectAMINE.  We optimized the two transfection
methods by varying the DNA-transfecting agent ratios (Fig. 2A).  The DEAE-dextran gave
optimal transfection at the concentration of about 100-200 g/ml per g DNA whereas the
LipofectAMINE showed optimal transfection at 12 g/ml per g DNA.  At their optimal
concentrations, LipofectAMINE was approximately 8-fold more effective than DEAE-dextran
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and showed minimal cellular toxicity as demonstrated by LDH assay.  Higher concentrations
of DEAE-dextran, i.e., >300 µg/ml, substantially increased cellular toxicity without
significantly improving gene transfer efficiency (Fig. 2B). In all studies, no significant
cytotoxicity was observed when DNA was used alone in the absence of transfecting agents.
i.e., <1%.
The observation that LipofectAMINE was more effective than DEAE-dextran is
contradictory to a recent report by Mack et al. (1998) who showed that LipofectAMINE was
toxic to the cells and thus was less effective than DEAE-dextran.  The basis for this
discrepancy is not clear but may be due to the differences in transfection conditions and
quality of the transfecting agents, as well as the assay methods used.  In the previous study,
Mack et al. (1998) did not report how cellular toxicity was detected.  It appears that a direct
morphologic examination of cell death was used.  In our study, a sensitive LDH assay was
used to assess cellular toxicity.  At the level of cellular toxicity reported in this study, no
apparent cell death could be directly observed.  Another possibility that could contribute to
the observed discrepancy is the difference in cell type used in the two studies.  Previous
study by Mack et al. (1998) utilized primary cultures of macrophages while our study utilized
continuous macrophage cultures.  While both cells are of macrophage origin, they may
respond differently to gene transfection.  Further studies to examine the differences in
enzymatic activities and cellular responsiveness between these cells may shed light on this
discrepancy.
Effect of Protamine Sulfate on Transfection
Protamine sulfate has been shown to promote lipid-based gene transfer in different
cell types (Sorgi et al., 1997).  However, its effect in macrophages has not been reported.  In
this study, we tested whether protamine can also enhance gene transfer efficiency in
macrophages.  Fig. 3B shows a dose-dependent increase in macrophage transfection by
protamine.  Maximum transfection was observed at the protamine concentration of about 1
µg/ml and LipofectAMINE concentration of 12 µg/ml per µg DNA. Similar results are seen
with β-gal reporter plasmid (Fig. 3C). This enhanced transfection was about 23-fold more
effective than DEAE-dextran-mediated gene transfer (Fig. 3A).  Protamine by itself or in
combination with DEAE-dextran had no significant effect on gene transfection (results not
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shown).  At the concentrations tested, protamine caused no significant toxic effect to the
cells.
Protamine has been proposed to increase lipid-mediated gene transfection by
condensing DNA into a compact structure, which promotes DNA cellular entry and
enzymatic stability (Kabanov and Kabanov, 1995).  Other polycationic condensing agents
such as polylysine have also been shown to possess this property.  However, protamine
appears to be more effective than other condensing agents despite of the fact that they
possess a similar condensing activity (Kabanov and Kabanov, 1995).  It has been
suggested that protamine, due to the presence of nuclear localization signals in its amino
acid sequence, can potentiate gene expression by increasing the nuclear translocation of
DNA (Sorgi et al., 1997).  While we did not demonstrate such effect of protamine in this
study we found that protamine can effectively enhance transfection activities of all liposomal
agents tested (see below).  Because of its simplicity, versatility, and ease of use, this
compound could be readily used as an adjuvant in a variety of gene transfer protocols.
Gene Transfer Mediated by Different Liposomal Formulations
Different liposomal formulations including LipofectAMINE, Lipofectin, and DOTAP
were further tested for their gene transfer efficiency in an attempt to determine the most
efficient system for transfecting macrophages. All liposomal formulations were optimized to
their best efficiency both in the presence or absence of protamine (Fig. 4A).  At their optimal
concentrations and in the absence of protamine, LipofectAMINE was found to be most
effective, followed by Lipofectin and DOTAP.  DOTAP was as equally effective as the
DEAE-dextran while Lipofectin was 3-fold more effective.  In the presence of protamine,
LipofectAMINE showed a 4-5-fold increase in transfection efficiency over Lipofectin and at
least 10- to 12-fold increase over DOTAP (Fig. 4A). Transfection with β-gal reporter plasmid
also showed that LipofectAMINE was far more effective than Lipofectin or DEAE-Dextran
(Fig. 4B). The increased efficiency of LipofectAMINE over other cationic liposomes may be
attributed to its greater number of positively charged groups, which could condense DNA
more efficiently than the monovalent lipid Lipofectin and DOTAP.
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II.5. CONCLUSION
We have developed a simple, efficient and reproducible method of transfection for
macrophages.  Transient transfection with our optimized delivery system resulted in a high
transgene expression compared to other existing methods of transfection.  The
macrophages transfected with this system were >95% viable as determined by LDH assay.
We have successfully applied this technique for the stable transfection of macrophages.
The transfection protocol permits the study of gene regulation in adherent macrophage
cultures and may be applicable to in vivo macrophage gene transfer.
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II.6. FIGURES
Fig. 1.  Comparison of Gene Transfection in Different Cell Lines.   Cells (1x106/ml) were
transfected for 4 h at 37oC with reporter gene CMV-luc (A) or CMV- -gal (B) (1 g/ml) in the
presence or absence of LipofectAMINE (12 g/ml).  This amount of LipofectAMINE was
optimized for macrophage transfection (see Fig. 2).  Two days post-transfection, the cells
were washed, lysed, and measured for luciferase activity or were stained for -gal as
described in the Methods section.  Each data point represents the mean (with standard
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Fig. 2. Effects of DEAE-Dextran and LipofectAMINE Concentration on (A) Transfection
Efficiency and (B) Cellular Toxicity of Macrophage RAW 264.7 Cells.  Cells (1x106/ml)
were incubated with transfection media that contained increasing amounts of DEAE-dextran
(0-200 g/ml) or LipofectAMINE (0-18 g/ml) in the presence of pCMV-luc (1 g/ml).  Two
days post-transfection, the cells and supernatants were collected and analyzed for
luciferase and LDH activities as noted in the Methods section.  Each data point represents
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Fig. 3.  Effect of Protamine Sulfate on LipofectAMINE-Mediated Gene Transfection.
(A) Comparison of gene transfection mediated by DEAE-dextran (100 g/ml) and
LipofectAMINE/protamine (12/1 g/ml) in macrophage RAW 264.7 cells.  (B) Varying
amounts of protamine sulfate (0-2 g/ml) were added to transfection media containing
LipofectAMINE (12 g/ml) and pCMV-luc (1 g/ml).  Analysis of luciferase gene expression
was performed as described in the Methods section. Each data point represents the mean
(with standard deviation) of quadruplicate samples and the data are normalized to protein
content. (C) Comparison of gene transfection mediated by (a) DNA (CMV-gal, 1 g) alone,
(b) DNA + LipofectAMINE (12 g/ml) and (c) DNA + LipofectAMINE/protamine (12/1 g/ml).




































Fig. 4.  Comparison of Transfection Activity of Different Liposomal Formulations in
Macrophage RAW 264.7 Cells.   Each liposomal formulation was optimized for their
transfection efficiency by varying the amount of liposome per 1 g/ml of DNA per well.  The
data represent the maximum values of gene expression for each liposomal formulation, both
in the absence or presence of protamine which was similarly optimized.  Transfection,
luciferase and -gal assay were performed as noted in the Methods section.  Each data
point represents the mean (with standard deviation) of quadruplicate samples and the data



































Burkholder, J.K., Decker, J., and Yang, N.S. (1993) Rapid transgene expression in
lymphocyte and macrophage primary cultures after particle bombardment-mediated
gene transfer.  J Immunol Meth 165, 149-156.
Daumler, R. and Zimmermann, U. (1989) High yields of stable transformants by hypo-
osmolar plasmid electroinjection.  J Immunol Meth 122, 203-210.
Economou, J.S., Rhoades, K., Essner, R., McBride, W.H., Gasson, J.C., and Morton, D.L.
(1989) Genetic analysis of the human tumor necrosis factor alpha/cachectin
promoter region in a macrophage cell line.  J Exp Med 170, 321-326.
Hess, J.L., Clements, J.E., and Narayan, O. (1985) Cis- and trans-acting transcriptional
regulation of visna virus.  Science 229, 482-485.
Kabanov, A.V. and Kabanov, V.A. (1995) DNA complexes with polycations for the delivery
of genetic material into cells.  Bioconj Chem 6, 7-20.
Mack, K.D., Wei, R., Elbagarri, A., Abbey, N., and McGrath, M.S. (1998) A novel method for
DEAE-dextran mediated transfection of adherent primary cultured human
macrophages.  J Immunol Meth 211, 79-86.
Pierce, G.F. (1990) Macrophages: important physiologic and pathologic sources of
polypeptide growth factors.  Am J Respir Cell Mol Biol 2, 233-234.
Roussel, M.F., Rettenmier, C.W., and Sherr, C.J. (1988) Introduction of a human colony
stimulating factor-1 gene into a mouse macrophage cell line induces CSF-1
independence but not tumorigenicity.  Blood 71, 1218-1225.
Rupprecht, A.P. and Coleman, D.L. (1991) Transfection of adherent murine peritoneal
macrophages with a reporter gene using DEAE-dextran.  J Immunol Meth 144, 157-
163.
Sorgi, F.L., Bhattacharya, S., and Huang, L. (1997) Protamine sulfate enhances lipid-
mediated gene transfer.  Gene Ther 4, 961-968.
- 45 -
Stief, A., Winter, D.M., Stratling, W.H., and Sippel, A.E. (1989) A nuclear DNA attachment




Mechanisms of Endotoxin-Induced Inactivation
of Transgene Expression in Macrophages
- 47 -
III.1. ABSTRACT
Endotoxin, the lipopolysaccharide (LPS) component of gram-negative bacteria, is a
common contaminant of plasmid DNA preparations.  The present study investigates the
effect of endotoxin on gene transfection efficiency and the role of reactive oxygen species
(ROS) in this process.  Gene transfection studies were performed in various cell types using
CMV-luciferase as a reporter plasmid and cationic liposome as a transfecting agent.  The
presence of endotoxin in plasmid DNA preparations severely limited transgene expression
in macrophages, but had little or no effect in other cell types tested.  This decreased
transfection was dependent on ROS-mediated cellular toxicity induced by endotoxin.
Neutralizing endotoxin by the addition of polymyxin B effectively increased transfection
efficiency and reduced toxicity.  Electron spin resonance (ESR) studies confirmed the
formation of ROS in endotoxin-treated cells and their inhibition by free radical scavengers.
The ROS scavenger PBN, catalase (H2O2 scavenger), and sodium formate (
.OH scavenger)
effectively inhibited endotoxin-induced effects, while superoxide dismutase (SOD)(O2
-
scavenger) had lesser effects.  These results indicate that multiple oxidative species are
involved in the transfection inactivation process, and that .OH radicals, formed by H2O2–
dependent, metal-catalyzed Fenton reaction, play a major role in this process.
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III.2. INTRODUCTION
Macrophages play an important role in host defense against noxious substances and
are involved in a variety of disease processes including autoimmune diseases, infections
and inflammatory disorders [see (Lewis and McGee, 1992) for review].  Molecular analysis
of macrophage functions can be accomplished by gene transfection assays.  However, gene
transfection in macrophages has proven difficult due to their refractory nature.  While over
the years, numerous efforts have been made to improve gene transfection of macrophages
(Burkholder et al., 1993; Daumler and Zimmermann, 1989; Mack et al., 1998; Rupprecht
and Coleman, 1991), their transfection is still poor. The lack of understanding of the causes
that contribute to the refractory nature of macrophages during gene transfection is partly
responsible for this limited success.  Since macrophages are known to be highly susceptible
to endotoxin stimulation and endotoxin is a major contaminant of plasmid DNA preparations
used in most transfection studies, we hypothesized that the presence of contaminating
endotoxin may contribute to this low transfection.  The present study was undertaken to test
this hypothesis and to elucidate the mechanisms underlying the cellular unresponsiveness
of macrophages to gene transfection.
Endotoxin (LPS) is known to be an extremely bioactive substance and a potent
stimulator of immune cells (Morrison and Ryan, 1987; Wright, 1991).  LPS consists of a
variable polysaccharide domain covalently attached to a lipid domain (lipid A).  LPS
mediates most of its effects by binding to macrophages and inducing the production of many
cellular mediators, including pro-inflammatory cytokines such as TNF and IL-1 (Raetz,
1990), fatty acid metabolites (Raetz, 1990), and reactive oxygen species (ROS) (Guthrie et
al., 1984).  ROS are known to exert multiple effects on cells and tissues and are involved in
a variety of pathological processes.  They can cause DNA damage, lipid peroxidation,
protein modification and activation of certain nuclear transcription factors such as AP-1 and
NF-B (Meyer et al., 1994; Remacle et al., 1995).  In the present study, we tested whether
ROS are involved in the transfection inactivation process of macrophages.
LPS has been shown to reduce gene transfection efficiency in non-immune cells
(Weber et al., 1995), however its mechanism of action is not known.  We report here that
cellular toxicity induced by LPS is responsible, at least in part, for the decreased transfection
efficiency in macrophages.  Since macrophages are the primary cellular target for LPS
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stimulation, we postulated that this cell type may be more susceptible to LPS effects.  We
examined the role of ROS generation by macrophages in transfection efficiency and
cytotoxicity.  Our hypothesis is that if ROS are responsible for such effects, then blocking
these reactive species, i.e., by free radical scavengers, would increase transfection
efficiency and decrease cellular toxicity.  We also attempted to identify key reactive species
involved in the process.  The specific questions to be addressed in this study are: 1) Are
macrophages more susceptible to LPS contamination of plasmid DNA than other cell types?
2) What is the underlying mechanism of LPS-induced cellular toxicity in macrophages?  3)
Can free radical scavengers decrease this toxicity and do they reverse LPS-induced





 Cell lines including the macrophage RAW 264.7 and NR383, alveolar epithelial
A549, kidney embryonic 293, and liver HEPG2 were obtained from the American Type Cell
Culture Collection (Rockville, MD).  The cells were grown in DMEM supplemented with 10%
fetal bovine serum (FBS), 2 mM L-glutamine, and 100 U/ml penicillin-streptomycin.  They
were maintained at 37oC in a humidified atmosphere containing 5% CO2.  Prior to use, cells
were briefly trypsinized or mechanically scraped and centrifuged.  They were plated at
~1x106 cells/ml in 12-well tissue culture plates one day before transfection studies.
Plasmid DNA
The expression vector CMV-luciferase contains the promoter-enhancer region of
Cytomegalovirus upstream from the luciferase gene (kindly provided by Dr. Leaf Huang,
University of Pittsburgh).  The plasmid was purified using the Qiagen Endofree or regular
ion-exchange plasmid kits (Qiagen, Chatsworth, CA) according to the manufacturer’s
instructions.  The content of endotoxin in plasmid DNA preparations was determined by
using the chromogenic Limulus amebocyte lysate assay (Kinetic-QCL, BioWhittaker,
Walkersville, MD) according to the manufacturer’s instructions.  In studies designed to study
the effect of endotoxin on gene transfection efficiency, specified amounts of LPS (E. coli
0111:B4, 1 EU/g) (Sigma, St. Louis, MO) was added to the plasmid preparations.
Liposomal Transfection
Approximately 1x106 cells were plated on a 12-well plate and allowed to grow for 24
hours before the transfection.  The plasmid DNA (1 g/ml) was diluted in 200 l of DMEM
(GIBCO BRL Life Technologies) and the DNA condensing agent protamine sulfate (0.1-2
g/ml) (Sigma, St. Louis, MO) was added to the DNA.  The liposome (1-20 g/ml) was
diluted in 200 l of DMEM.  The diluted DNA and liposome samples were combined and
incubated at room temperature for 15-20 min.  In some studies, indicated amounts of
polymyxin B sulfate, PBN, SOD, catalase, and sodium formate (Sigma) were also added to
the transfection medium.  Cells with transfection reagents were incubated for 4 hours.
Transfection medium was then replaced with growth medium containing 10% FBS.  Cells
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were cultured for an additional 48 hours before the level of gene expression was
determined.  All transfections were conducted under sterile conditions and duplicate plates
were tested for each condition.
Measurement of Luciferase Activity
Luciferase synthesized during the in vitro translation was quantitated by the assay of
enzyme-dependent light production using a luciferase assay kit (Promega, Madison, WI).
Cells were washed twice with PBS and incubated at room temperature for 10 min in the
presence of 250 µl of lysis buffer (Promega) and then centrifuged at 12000g.  Ten
microliters of each sample was placed in a 5-ml polystyrene test tube and the tubes were
then loaded into an automated luminometer (BioRad, Hercules, CA).  At the time of
measurement, 100 µl of luciferase substrate was automatically injected into each sample,
and total luminescence was measured over a 20-sec time interval.  Output is quantitated as
relative light units (RLU).  Protein content in the supernatant was determined by BCA protein
assay reagent (Pierce, Rockford, IL).  Luminescence detected was standardized per µg
protein present in the supernatant.
LDH Activity
LDH assay was performed to assess the effect of test agents on cellular toxicity.
Cells were treated with plasmid DNA, LPS, and transfecting agents, either individually or in
combination as indicated.  After the treatments, the cell supernatants were collected and
assayed for LDH activity.  LDH activity was determined by monitoring the oxidation of
pyruvate coupled with the reduction of NAD at 340 nm using an LDH assay kit (Roche
Diagnostic Systems, Montclair, NJ).  The assay was performed on Cobas Fara II Analyzer
(Roche Diagnostic Systems).  One unit per liter of LDH activity is defined as the amount of
enzyme that converts 1 µmol of lactate to 1 µmol of pyruvate with the concomitant reduction
of 1 µmol of NAD to 1 µmol of NADH per minute per liter of sample in the assay procedure.
Free Radical Measurements
The ESR spin trapping technique was used to detect short-lived free radical
intermediates. Spin trapping is necessary because of the reactive nature of the free radicals
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to be studied. This technique involves an addition-type reaction of a short-lived radical with a
diamagnetic compound (spin trap) to form a relatively long-lived free radical product, the so-
called spin adduct, which can be studied by conventional ESR. The intensity of the spin
adduct signal corresponds to the amount of short-lived radicals trapped, and the hyperfine
splittings of the spin adduct are generally characteristic of the original, short-lived, trapped
radical. All measurements were conducted with a Varian E9 ESR spectrometer and a flat
cell assembly.  Hyperfine splittings were measured (to 0.1G) directly from magnetic field
separations using potassium tetraperoxochromate (K3CrO8) and 1,1-diphenyl-2-
picrylhydrazyl (DPPH) as standards.  Reactants were mixed in test tubes in a total volume of
0.5 ml.  The reaction mixture was then transferred to a flat cell for ESR measurement.  All




Macrophages are Difficult to Transfect
To evaluate the relative transfection efficiency of macrophages compared to other
cell types, we transfected various cell lines from different origins including the macrophage
RAW 264.7 and NR383, kidney embryonic 293, alveolar epithelial A549 and liver HEPG2
cells with the CMV-luciferase reporter plasmid. The results of this study (Fig. 1). show that
maximum luciferase activity was observed in HEPG2 cells, followed by embryonic 293,
epithelial A549, and macrophage RAW 264.7 cells and NR383, respectively.  In the absence
of transfecting agents, all four cell lines exhibited minimum luciferase activity.  These results
indicate that gene transfection is cell type-dependent and that macrophages are relatively
difficult to transfect compared to other cell types.
Endotoxin Reduces Transfection Efficiency and Increases Cellular Toxicity
Endotoxin is known to be a frequent contaminant of plasmid DNA preparations
(Cotten et al., 1994) and a potent stimulator of macrophages (Morrison and Ryan, 1987;
Wright, 1991).  We therefore tested whether the presence of contaminating endotoxin could
contribute to the observed low transfection efficiency in macrophages.  To test this
possibility, we used highly purified plasmid preparations which we obtained by using the
Qiagen Endofree plasmid preparation kit, and tested the effect of added LPS on gene
transfer efficiency.  Plasmid samples prepared by this method were found to contain <0.1
Endotoxin Unit (EU) per g plasmid DNA as determined by the Limulus amebocyte lysate
assay.  This amount of endotoxin is typically 100-10,000 times less than that obtained by
conventional methods of DNA preparation such as anion-exchange chromatography and
silica-based adsorption (Weber et al., 1995).  Not surprisingly, transfection of macrophages
with the Endofree plasmid was thirty times greater than that of plasmid prepared by anion-
exchange chromatography (Fig. 2).  Fig. 2A shows that the addition of small amounts of
LPS (0-0.5 g/ml or 0-5 EU/ml) greatly reduced the transfection efficiency of macrophages.
In contrast, LPS at the same concentration range had no significant effect on gene
transfection efficiency in other cell types tested (Fig. 3A).  These results suggest that
macrophages are especially sensitive to LPS and that this increased susceptibility may be
responsible for their poor transfection efficiency.  To test whether the reduced transfection is
associated with cellular toxicity potentially caused by LPS, we studied the effect of LPS on
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cellular LDH release.  Fig. 3B shows that at the same concentrations used in gene
transfection studies, LPS caused a significant toxic effect in macrophages but had only
minimal effect in other cell types.  These results suggest that the low transfection efficiency
in macrophages may be caused by LPS-mediated cellular toxicity.
The role of endotoxin in macrophage toxicity is further studied by using the endotoxin
neutralizing agent polymyxin B.  Polymyxin B is a polycationic antibiotic that has been widely
used to neutralize the effects of LPS (Storm et al., 1977).  Treatment of the cells with this
agent during gene transfection decreased cellular toxicity (Fig. 4A) and reversed the LPS-
induced decrease in transfection (Fig. 4B).  Thus, these results confirm that the observed
low transfection is due to the cytotoxic effects of endotoxin.
ROS are Involved in LPS-Mediated Toxicity
LPS stimulation of macrophages has been reported to cause activation and release
of ROS (Gossart et al., 1996).  Since ROS are known to be involved in a number of
pathological processes, we postulated that ROS may be responsible for LPS-induced
toxicity and reduced transfection.  To test this possibility, we treated the cells with PBN
(ROS scavenger) and study its effects on LPS-induced toxicity and transfection activity.
PBN has been used in previous studies as a scavenger of ROS (Gossart et al., 1996).  Our
results show that PBN effectively inhibited LPS-induced toxicity (Fig. 4A) and restored
transfection activity (Fig. 4B).  Thus, our results support the role of ROS in the process.
Subsequent studies using specific ROS scavengers (see below) further confirm these
results.
Hydroxyl Radical (.OH) is the Primary Reactive Species Responsible for LPS-Induced
Effects
Since PBN is a non-specific ROS scavenger, the identity of specific oxygen species
involved in this process is not known.  To identify such species, we used specific ROS
inhibitors, including SOD (O2
- scavenger), catalase (H2O2 scavenger), and sodium formate
(.OH scavenger) to study the effects on LPS.  O2
-, H2O2, and 
.OH are three major reactive
species produced by macrophages (Drath and Karnovsky, 1975; Gee et al., 1970;
Rojanasakul et al., 1993) and thus are the primary focus of our investigation.  Figs. 5A and
5B show that all three scavengers had an inhibitory effect on cellular toxicity and
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transfection activity.  However, the effects were more pronounced in the case of catalase
and sodium formate and lesser effects were observed with SOD.  It should be noted that all
three scavengers were tested at different concentrations, however only optimal
concentrations of each scavenger are presented here.  The results obtained suggest that
multiple ROS are involved in the toxicological process and that H2O2 and 
.OH play a greater
role.  Since H2O2 has been reported to be a major source of 
.OH formation in macrophages,
i.e., via metal-catalyzed Fenton reaction [Mn+ + H2O2 -> M
(n+1)+ + OH- + .OH] (Rojanasakul et
al., 1993), and since .OH is known to be highly reactive, we suggest that .OH may be the
primary oxidative species responsible for the observed effects induced by LPS.  Supporting
this notion is the fact that sodium formate, a scavenger of .OH radicals, was equally effective
in decreasing toxicity and restoring transfection as catalase, and that catalase can inhibit
.OH radicals in macrophages as further demonstrated in our ESR studies (see below).
To confirm that .OH radicals were actually formed during LPS activation, ESR
studies using the spin trap DMPO were carried out. Cells were treated with LPS in the
presence or absence of ROS scavengers. Fig. 6 shows that in the presence of LPS, an ESR
spectrum consisting of a 1:2:2:1 quartet pattern, which is characteristic of DMPO-.OH adduct
(Oberly, 1984), was observed.  Addition of the .OH scavenger sodium formate to the system
decreased the intensity of the DMPO-.OH signal, thus confirming the formation of .OH
induced by LPS. Interestingly, catalase whose function is to scavenge H2O2 also inhibited
.OH formation. These results are consistent with previous studies by our group which
demonstrated that H2O2 can react with endogenous metal ions to form 
.OH via the Fenton
reaction (Rojanasakul et al., 1993). The results also explain the observed comparable
effects of catalase and sodium formate in our toxicity and transfection studies.
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III.5. DISCUSSION
Transfection of macrophages represents a significant challenge in gene regulation
studies that utilize these cells. Because of their crucial function in a variety of biological
processes and pathologies, these cells also represent important targets for gene therapies.
Using liposome-based gene transfection assay, we have shown that macrophages are
difficult to transfect when compared to other cell types. Macrophages are sensitive to the
content of contaminating endotoxin and hence are sensitive to the method of DNA
preparation.
Previous studies have shown that the presence of contaminating endotoxin in
plasmid preparations can reduce gene transfection efficiency in other cell types (Weber et
al., 1995).  However, this effect is generally observed at high levels of endotoxin, i.e., >100
EU/ml.  In this study, we found that macrophages are susceptible to endotoxin at very low
levels (0-5 EU/ml). At these concentrations, gene transfection was greatly diminished in
macrophages but was relatively unaffected in other cell types. These results indicated that
macrophages are particularly sensitive to endotoxin contamination and that this increased
susceptibility may be responsible for their poor transfection efficiency.
The mechanism by which endotoxin decreases gene transfection in macrophages is
not known. We suggest that this decreased efficiency may be associated with cellular
toxicity induced by endotoxin.  Supporting this notion is the evidence that endotoxin induced
cellular toxicity and also decreased gene transfection in macrophages, the effects that were
not observed in other cell types tested. The role of cellular toxicity in decreasing transfection
efficiency is confirmed by treatment of cells with polymyxin B during transfection.  Polymyxin
B is a polycationic antibiotic that has been widely used to neutralize the effects of LPS.
Polymyxin B is known to bind lipid A portion of LPS with high affinity (Morrison and Jacobs,
1976).  The lipid A portion has also been shown to be responsible for most of the biological
activities of LPS (Morrison and Ryan, 1987; Raetz, 1990).  We have observed in this study
that the addition of polymyxin B to the transfection medium effectively inhibited the cytotoxic
effect of endotoxin and restored gene transfection efficiency of macrophages.
Endotoxin is known to activate macrophages and induce the production of various
cellular mediators including ROS (Guthrie et al., 1984; Raetz, 1990).  Consistent with these
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studies, our ESR and ROS scavenging studies indicated the formation of ROS in our
system.  To test whether the ROS generated are responsible for the decreased transfection
induced by LPS, we treated the cells with different ROS scavengers during transfection. All
scavengers increased gene transfection efficiency, thus supporting the role of ROS in this
process.  These scavengers also decreased cellular toxicity induced by LPS, further
substantiating the relationship between these two processes.  The observation that all ROS
scavengers exhibited LPS inhibitory effects and that PBN, a general ROS scavenger, was
more effective than other scavengers in neutralizing the LPS effects also indicated that
multiple ROS are involved in the process.  Careful analysis of the test results further showed
that O2
- radicals play a less significant role and .OH radicals formed by H2O2–dependent,
metal-catalyzed Fenton reaction play a major role in the process.
The conclusions of this study are: 1) LPS decreases transfection efficiency in
macrophages due to its toxic effect; 2) LPS-induced ROS generation is involved in this
process; 3) inactivating LPS by addition of polymyxin B or addition of ROS scavengers
decreases the toxicity associated with LPS; and 4) .OH radicals appear to be the major
reactive species responsible for LPS-induced toxicity and reduced transfection.  We report
here, for the first time, the role of ROS in causing decreased transfection in macrophages.
The results of this study should provide useful information concerning the design of safe and
effective gene delivery systems for macrophages.
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III.6. FIGURES
Fig. 1. Comparison of Gene Transfection in Different Cell Lines. Cells (1x106/ml) were
transfected with the reporter plasmid CMV-luciferase (1 µg/ml) in the presence or absence
of transfecting agents (LipofectAMINE, 12 µg/ml; protamine, 1 µg/ml) for 4 h at 37oC. The
transfection conditions were optimized for maximum transfection of macrophages. Two days
post-transfection, the cells were washed, lysed, and measured for luciferase activity. Data





































Fig. 2. Effect of DNA Preparation on Gene Transfer Efficiency.  Macrophage RAW 264.7
cells (1x106/ml) were transfected with either Endofree or anion-exchange plasmid CMV-
luciferase (1 g/ml) in the presence or absence of transfecting agents (LipofectAMINE, 12
g/ml; protamine, 1 g/ml) for 4 h at 37oC. Two days post-transfection, the cells were
washed, lysed, and measured for luciferase activity. Values are means + SD; n = 4. * p <


























Fig. 3. Effects of Endotoxin on Transfection Efficiency ( A) and Cellular Toxicity ( B) in
Different Cell Lines. Cells (1x106/ml) were transfected with Endofree CMV-luciferase (1
g/ml) in the presence of transfecting agents (LipofectAMINE, 12 g/ml; protamine, 1 g/ml)
for 4 h at 37oC. Varying amounts of LPS (0–0.5 g/ml) were also added to the transfection
medium during transfection. Two days post-transfection, the cells and supernatants were
collected and analyzed for luciferase and LDH activities. Values are means + SD; n = 4. * p
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Fig. 4. Effects of Polymyxin B and PBN on LPS-Induced Toxicity (A) and Transfection
Efficiency (B). Cells (1x106/ml) were transfected with CMV-luciferase (1 µg/ml) in the
presence of transfecting agents (LipofectAMINE, 12 µg/ml; protamine, 1 µg/ml) for 4 h at
37oC. Polymyxin B (1 µg/ml) and PBN (2 mM) were added to the transfection medium in
different treatment groups. Two days post-transfection, the cells and supernatants were
collected and analyzed for luciferase and LDH activities. Values are means + SD; n = 4. * p
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Fig. 5. Effects of ROS Scavengers on LPS-Induced Toxicity (A) and Transfection
Efficiency (B). Cells (1x106/ml) were transfected with CMV-luciferase (1 µg/ml) in the
presence of transfecting agents (LipofectAMINE, 12 µg/ml; protamine, 1 µg/ml) for 4 h at
37oC. SOD (100 µg/ml), catalase (100 u/ml), and sodium formate (5 mM) were added to the
transfection medium in different treatment groups. Two days post-transfection, the cells and
supernatants were collected and analyzed for LDH and luciferase activities. Values are



















Untreated     LPS          LPS          LPS         LPS



















Untreated     LPS          LPS          LPS         LPS




Fig. 6. ESR Measurements of LPS-Induced ROS Generation. A: ESR spectrum recorded
1 h after an addition of LPS (10 µg/ml) to macrophage RAW 264.7 cells (1x106/ml) in the
presence of spin trapper DMPO (100 mM). B: same as A but with no LPS treatment. C:
same as A but with catalase (100 u/ml) added. D: same as A but with sodium formate (5
mM) added. The spectrometer settings were as follows: receiver gain, 1.5x105; time
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SECTION IV
Mechanism of Interleukin-10-Mediated Inhibition
of Nuclear Factor κB Activation in Macrophages
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IV.1. ABSTRACT
Interleukin-10 (IL-10) is a pleiotropic cytokine that controls inflammatory processes
by suppressing the production of proinflammatory cytokines which are known to be
transcriptionally regulated by nuclear factor κB (NF-κB).  Although still controversial, IL-10
has been shown to inhibit NF-κB activation through a process that involves proteolytic
degradation of inhibitory subunit IκBα.  What is not known however is the mechanism by
which IL-10 exerts its effect on IκBα degradation. The present study investigates the
possible role of reactive oxygen species (ROS) and their inhibition by IL-10 in NF-κB
activation and IκBα degradation in macrophages. Treatment of the cells with
lipopolysaccharide (LPS) caused activation of NF-κB and rapid proteolysis of IκBα, as
determined by the electrophoretic mobility shift assay (EMSA), gene transfection and
Western blot.  IL-10 pretreatment inhibited both NF-κB activation and IκBα degradation.
Both these processes were also inhibited by ROS scavengers, catalase (H2O2 scavenger)
and sodium formate (.OH scavenger), but were minimally affected by superoxide dismutase
(SOD)(O2
- scavenger). These results suggests that .OH radicals, formed by a H2O2–
dependent, metal-catalyzed Fenton reaction, play a major role in this process.  Electron spin
resonance (ESR) studies confirmed the formation of .OH radicals in LPS-treated cells.
Addition of IL-10 inhibited both IκBα degradation and generation of .OH radicals in response
to LPS stimulation.  These results demonstrate, for the first time, direct evidence for the role
of IL-10 in ROS-dependent NF-κB activation.
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IV.2. INTRODUCTION
Advances in molecular and cellular biology have identified the cellular mediators that
regulate many disease processes.  One such mediator, IL-10, has been identified as an
important regulator of the immune and inflammatory systems (Moore et al., 1993; de Vries,
1995).  IL-10 is an anti-inflammatory cytokine that is regularly produced during inflammatory
processes in vivo, usually by the same cells that release inflammatory mediators (e.g.,
monocytes, macrophages, T cells).  It inhibits the production of inflammatory cytokines such
as IL-1, IL-6, and tumor necrosis factor (TNFα) by macrophages stimulated with LPS and
interferon (Fiorentino et al., 1991).
In animal models of sepsis, IL-10, given before or soon after Gram-negative bacterial
endotoxin has reduced TNFα production, hypothermia, and death (Howard et al., 1993).  It
was found that mice are more sensitive to LPS-induced shock by treatment with anti-IL-10
antibodies (Ishida et al., 1994).  It was also found that IL-10 deficient mice developed severe
enterocolitis and that IL-10 is an essential immunoregulator in the intestinal tract (Kuhn et
al., 1993).  Because of its potent anti-inflammatory effects, IL-10 has been implicated in a
number of inflammatory conditions such as sepsis, chronic arthritis, and inflammatory bowel
disease.
NF-κB is a transcription factor that regulates gene transcription of many of the
proinflammatory cytokines that are suppressed by IL-10 (Baldwin, 1996).  NF-κB is a
ubiquitous transcription factor that plays a central role in regulating gene expression of a
number of proinflammatory cytokines that are released as a consequence of macrophage
activation [reviewed in (Baeuerle and Henkel, 1994)].  Thus, suppression of NF-κB activity is
potentially a mechanism for regulating inflammatory responses.  NF-κB is most frequently
composed of two DNA-binding subunits, p50 and p65 (Baeuerle and Henkel, 1994) and is
present cytoplasmically in an inactive form in resting cells.  The nuclear translocation and
DNA binding of NF-κB dimers is tightly controlled by accessory proteins called IκB subunits
(Baldwin, 1996).  NF-κB is activated by a diverse range of stimulants including LPS, UV
light, H2O2, and inflammatory cytokines such as IL-1 and TNFα (Baldwin, 1996; Baeuerle,
1995).  When cells are treated with NF-κB inducers, rapid proteolysis of IκBα proteins
occurs and NF-κB dimers dissociate from the NF-κB/IκB complex (Henkel et al., 1993;
Whiteside and Israel, 1997).  NF-κB inducers cause rapid phosphorylation of IκBα on two
- 69 -
serine residues (Brown et al., 1995; Traenckner et al., 1995) after which it is ubiquitinated
and finally degraded by the proteosomes (Chen et al., 1995).  Recently, the IκBα kinases
(IKK) responsible for the phosphorylation have been identified (Stancovski and Baltimore,
1997).  The release of IκBα exposes the nuclear localization sequence of NF-κB, and as a
result, NF-κB dimers rapidly appear in the nucleus where they bind DNA (Baeuerle and
Henkel, 1994).  A number of genes contain NF-κB binding sites that might control their
inducible expression (Lenardo et al., 1989).  Thus, certain genes regulated by NF-κB can be
transcriptionally activated within minutes after being exposed to the inducer.
The overall objective of this study is to investigate the effect of IL-10 on NF-κB
activation in macrophages and to elucidate the molecular mechanism involved in this
process.  Macrophages play an important role in host defense against noxious substances
and are involved in a variety of disease processes including autoimmune diseases,
infections and inflammatory disorders (Pierce, 1990).  While the role of IL-10 as an anti-
inflammatory molecule has been well established (Moore et al., 1993), the mechanism by
which it exerts its action is still not completely understood and the experimental results are
controversial.  While most studies have shown that IL-10 inhibits NF-κB activation (Romano
et al., 1996; Wang et al., 1995), there are others that report quite the opposite (Dokter et al.,
1996; Takeshita et al., 1996).  Similarly, the data on the effect of IL-10 on IκBα degradation
are contradictory (Clarke et al., 1998; Schottelius et al., 1999).  These differences can be
reasonably explained by the fact that IL-10 has a great diversity of action and the effect of
IL-10 on each cell is dependent on many factors, not all of which are understood.
Because macrophages are known to generate ROS in response to stimuli and
because ROS have been implicated as the common messenger involved in NF-κB
activation by diverse stimuli (Bonizzi et al., 2000; Bowie and O'Neill, 2000), we hypothesized
that IL-10 may exert its effect on NF-κB activation by changing the redox status of
stimulated cells through an ROS-dependent pathway.  The specific questions being
addressed in this study are: 1) Do ROS play a role in IL-10-mediated NF-κB signaling
pathway? 2) What are the effects of IL-10 on NF-κB activation and IκBα degradation in
macrophages? 3) What are the key reactive species involved in the process?  This is the
first study that directly demonstrates the inhibitory effect of IL-10 on ROS production.
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IV.3. MATERIALS AND METHODS
Cell Culture
The macrophage cell line RAW 264.7 was obtained from the American Type Cell
Culture Collection (Rockville, MD).  The cells were grown in DMEM (GIBCO BRL Life
Technologies) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and
100 U/ml penicillin-streptomycin.  They were maintained at 37oC in a humidified atmosphere
containing 5% CO2.  Prior to use, cells were briefly trypsinized or mechanically scraped and
centrifuged.  They were plated at ~1x106 cells/ml in 12-well tissue culture plates one day
before transfection studies.
Liposomal Transfection
Approximately 1x106 cells were plated on a 12-well plate and allowed to grow for 24
hours before the transfection.  The plasmid DNA NF-κB luciferase (1 µg/ml) was diluted in
200 µl of DMEM and the DNA condensing agent protamine sulfate (1 µg/ml) (Sigma, St.
Louis, MO) was added to the DNA.  The liposome (LipofectAMINE, GIBCO BRL Life
Technologies) (12 µg/ml) was diluted in 200 µl of DMEM.  The diluted DNA and liposome
samples were combined and incubated at room temperature for 15-20 min.  Cells with
transfection reagents were incubated for 4 hours.  Transfection medium was then replaced
with growth medium containing 10% FBS.  Thirty six hours after transfection the cells were
stimulated with LPS either in the presence or absence of other test agents.  Twelve hours
after stimulation, luciferase activity was measured as described below.  To account for the
potential cytotoxic effect caused by the transfecting agent, LPS, or other test agents during
the experiments, total cell protein was determined and used to normalize the measured
luciferase activity.  All transfections were conducted under sterile conditions and duplicate
plates were tested for each condition.
Stable Transfection
Cells were transfected with 1 µg of both CMV-mIL-10 (a kind gift from Dr. Tahara,
University of Pittsburgh) and pCDNA3 using the protocol above for transient transfection.
Two days after transfection, the medium was replaced with fresh complete medium
containing 20 µl of 75 µg/ml G418 solution.  Every two days the medium was changed and
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fresh G418 was added and this was cultured for 2 weeks.  Survived colonies were picked
and tested for their ability to produce IL-10 as determined by ELISA.  To ensure a
homogenous population of cells, positive colonies were subcloned and rescreened.  Control
cell line (RAW-control) was prepared the same way except that a control CMV plasmid
lacking IL-10 was used.
Measurement of Luciferase Activity
Luciferase synthesized during the in vitro translation was quantitated by the assay of
enzyme-dependent light production using a luciferase assay kit (Promega, Madison, WI).
Cells were washed twice with PBS and incubated at room temperature for 10 min in the
presence of 250 µl of lysis buffer (Promega) and then centrifuged at 12000g.  Ten
microliters of each sample was placed in a 5-ml polystyrene test tube and the tubes were
then loaded into an automated luminometer (BioRad, Hercules, CA).  At the time of
measurement, 100 µl of luciferase substrate was automatically injected into each sample,
and total luminescence was measured over a 20-sec time interval.  Output is quantitated as
relative light units (RLU).  Protein content in the supernatant was determined by BCA protein
assay reagent (Pierce, Rockford, IL).  Luminescence detected was standardized per µg
protein present in the supernatant.
Determination of TNFα Protein
In experiments where inhibition of TNFα produced by LPS stimulation had to be
studied, cells were stimulated with the indicated amount of LPS for 6 h at 37oC.  Cell-free
supernatants were then collected and assayed for cytokines by enzyme-linked
immunosorbent assay (ELISA) kits specific for murine TNFα and protein levels were
measured as specified by the manufacturer (Endogen).  The sensitivity of the assays ranged
from 15 to 31 pg/ml.  The coefficient of variation for all cytokine assays was <10%.
Oligonucleotides
Oligonucleotides (ON) were purchased from GIBCO BRL Life Technologies.  The
synthesized single-stranded ON were deprotected and desalted, and complementary
strands were denatured at 80oC for 5 min and annealed at room temperature.  The double-
stranded ON were labeled with (32P) dCTP (Amersham, Arlington Heights, IL) by using
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Klenow fragment (Bethesda Research Laboratories, Gaithersburg, MD), and the labeled ON
were used as probes in the electrophoretic mobility shift assay (EMSA).  The ON used in
this study contained the NF-κB sequence of IL-6 gene promoter (74-
TGGGATTTTCCCATGAGTCT-54).
Nuclear Extraction
Nuclear extracts were prepared as follows; 5x107 cells were treated with 500 µl lysis
buffer (50 mM KCl, 0.5% Nonidet P-40, 25 mM HEPES, 1 mM phenylmethylsulfonyl fluoride,
10 µg/ml leupeptin, 20 µg/ml aprotinin, 100 µM dithiothreitol) and kept on ice for 4 min.
Nuclei were pelleted by centrifugation at 20,000 RCF for 1 min and supernatants were
discarded.  The nuclei were washed once with the same buffer without Nonidet P-40 and the
nuclei were extracted in 300 µl extraction buffer (500 mM KCl, 10% glycerol, 25mM HEPES,
1mM PMSF, 10µg/ml leupeptin, 20µg/ml aprotinin, 100µM DTT).  After centrifugation at
20,000 RCF for 5 min, the supernatants were harvested.  The protein concentration of the
resulting nuclear protein extract were determined by BCA protein assay reagent (Pierce,
Rockford, IL) and the samples were diluted to 1 µg/µl with extraction buffer.  The nuclear
proteins were stored at -70oC.
Electrophoretic Mobility Shift Assay
The DNA-protein binding reaction was conducted in a 24-µl reaction mixture
including 3 µg nuclear protein extract, 1 µg poly dI.dC (Sigma), 3 µg BSA, and 12 µl of 2xY
buffer.  The mixture was incubated on ice for 10 min.  A total of 105 cpm of 32P-labeled
oligonucleotide probe was added, and the mixture was incubated for an additional 20 min at
room temperature and then loaded on a 5% acrylamide gel (GIBCO BRL) that had been
prerun at 110 V for 30 min with 0.5x Tris-borate-EDTA buffer.  The loaded gel was run at
200 V for 90 min, then dried, and exposed to X-OMAT film overnight (Eastman Kodak,
Rochester, NY) for autoradiography.  The film was developed after overnight exposure at -
70oC.
Western Blots
For intracellular IκBα degradation studies, whole-cell proteins were extracted.
Whole cell extracts were subjected to 12% SDS-polyacrylamide gel electrophoresis (SDS-
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PAGE).  Resolved proteins were transferred to a nitrocellulose membrane and incubated
with affinity-purified rabbit polyclonal anti-IκBα serum raised against a peptide
corresponding to amino acids 297-317 (mapping within the carboxyl-terminal domain of
human IκBα molecule).  After three 10-min washes with PBS/Tween-20, the membranes
were incubated with peroxidase-conjugated anti-rabbit immunoglobulin, and the antigen-
antibody complexes were detected using ECL Western blotting detection reagents
according to the manufacturer's instructions.
Free Radical Measurements
The ESR spin trapping technique was used to detect short-lived free radical
intermediates (Wang et al., 1999).  All measurements were conducted with a Varian E9 ESR
spectrometer and a flat cell assembly.  Hyperfine splittings were measured (to 0.1G) directly
from magnetic field separations using potassium tetraperoxochromate (K3CrO8) and 1,1-
diphenyl-2-picrylhydrazyl (DPPH) as standards.  Reactants were mixed in test tubes in a
total volume of 0.5 ml.  The reaction mixture was then transferred to a flat cell for ESR
measurement.  All measurements were carried out using 5,5-dimethyl-1-pyrroline-N-oxide
(DMPO)(Aldrich) as a spin trap.
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IV.4. RESULTS
Inhibition of LPS-Induced TNFα Production by IL-10
It has been suggested that the nuclear factor NF-κB mediates the transcriptional
activation of TNFα (Baeuerle and Henkel, 1994).  We tested whether IL-10 could inhibit NF-
κB-dependent TNFα expression.  RAW 264.7 macrophages were stimulated with LPS (10
ng/ml) for 6 h and cell culture supernatants were then assayed by ELISA for TNFα released.
Stimulation of cells with LPS resulted in the release of high concentrations of TNFα.
Pretreatment of cells with recombinant mouse IL-10 (rmIL-10) (1-50 ng/ml) 2 h prior to
stimulation with LPS (10 ng/ml) resulted in a dose-dependent inhibition (50-72%) in TNFα
production (Fig. 1A).  We also tested the inhibitory effect of IL-10 on TNFα production in a
stably transfected cell line (RAW IL-10) that constitutively expresses IL-10 protein.
Stimulation of RAW IL-10 with LPS showed much lower levels of TNFα compared to the
regular (RAW 264.7) or control cell line (RAW-control)  (Fig. 1B).
Effect of IL-10 on NF-κB Binding Activity and IκBα Degradation
EMSA studies were performed on stably transfected cells to study the effect of IL-10
on NF-κB activation (Fig. 2).  While LPS stimulation enhances NF-κB binding activity of
RAW 264.7 and RAW-control cells, this LPS-induced NF-κB activity was inhibited in RAW
IL-10 cell line.  This suggests that IL-10 is responsible for NF-κB inhibition.
To determine if IL-10 inhibited the transcriptional activation of NF-κB, RAW 264.7
cells were transiently transfected with an expression plasmid containing luciferase gene
transcribed from the NF-κB dependent promoter.  The transfected cells were treated with
LPS in the presence or absence of IL-10.  Fig. 3A shows that LPS treatment caused a 10-
fold increase in luciferase activity, which was inhibited by IL-10 in a dose-dependent
manner.  This data suggests that IL-10 not only prevents NF-κB-DNA binding but also
inhibits NF-κB induced transcription and hence, gene expression.
Since the activity of NF-κB is controlled by its interaction with IκBα, the next logical
step would be to test if IL-10 inhibits NF-κB activation via its effect on IκBα degradation.  To
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determine if the decreased DNA binding activity of NF-κB is due to inhibition of IκBα
proteolysis, we performed Western blot analysis on either RAW-control or RAW-IL-10 cells
stimulated with LPS (Fig. 3B).  Cell lysates were collected and immunoblotting for IκBα was
performed.  In the control cell line, LPS stimulation caused complete proteolysis of IκBα by
30 min.  RAW-control cells behave very similarly to regular RAW 264.7 cells.  This
degradation of IκBα is not seen in LPS-stimulated RAW-IL10 cells.  These results suggest
that IL-10 inhibits Iκ-Bα degradation.
Role of Reactive Oxygen Species in LPS-Stimulated Macrophages
The role of free radical reactions in LPS-induced NF-κB activation was examined
using specific ROS inhibitors, including SOD (O2
- scavenger), catalase (H2O2 scavenger),
and sodium formate (.OH scavenger).  Macrophages are known to generate free radicals in
response to stimuli.  O2
-, H2O2, and 
.OH are three major reactive species produced by
macrophages (Drath and Karnovsky, 1975; Gee et al., 1970) and thus are the primary focus
of our investigation.  As shown in Fig. 4A, cells treated with catalase and sodium formate
prior to LPS stimulation exhibited a decrease in NF-κB activity, while SOD pretreatment had
no effect on LPS-induced NF-κB activity.  It should be noted that all three scavengers were
tested at different concentrations, however only optimal concentrations of each scavenger
are presented here.
Western blots were employed to determine if these ROS scavengers inhibited NF-κB
activation due to the stabilization of IκBα.  RAW 264.7 cells were treated with the same
specific ROS scavengers SOD, catalase, and sodium formate before stimulation with LPS.
Consistent with the results above, addition of catalase and sodium formate inhibited LPS-
induced IκBα degradation, while SOD was not effective (Fig. 4B).  It must be noted that
pretreatment of cells with IL-10 also inhibited IκBα degradation (Fig. 4B).
The results obtained above suggest that ROS are involved in the process and that
H2O2 and 
.OH play a major role.  Since H2O2 has been reported to be a major source of 
.OH
formation in macrophages, i.e., via metal-catalyzed Fenton reaction [Mn+ + H2O2 -> M
(n+1)+ +
OH- + .OH], and since .OH is known to be highly reactive, we suggest that .OH may be the
primary oxidative species responsible for the observed effects induced by LPS.  Supporting
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this notion is the fact that sodium formate was equally effective as catalase in inhibiting NF-
κB activity and IκBα degradation.
Effect of IL-10 on Hydroxyl Radical Generation
Our results suggest that .OH radical may be the key species involved in NF-κB
activation.  To confirm that .OH radicals were actually formed during LPS activation, ESR
studies using the spin trap DMPO were carried out.  ESR spin trapping is a method that is
specific and sensitive and is considered to be the best technique for detection and
identification of free radical generation (Wang et al., 1999).  Cells were treated with LPS in
the presence or absence of IL-10 and ROS scavengers.  Fig. 5 shows that in the presence
of LPS, an ESR spectrum consisting of a 1:2:2:1 quartet pattern, which is characteristic of
DMPO-.OH adduct (Buettner, 1984), was observed. LPS-induced adduct formation
increased with time and reached a peak in an hour. Pretreatment of cells with IL-10 inhibited
LPS induced free radical generation (Fig. 5).  Addition of the .OH scavenger sodium formate
to the system decreased the intensity of the DMPO-.OH signal, thus confirming the
formation of .OH induced by LPS.  Interestingly, catalase whose function is to scavenge
H2O2 also inhibited 
.OH formation.  These results are consistent with previous studies by our
group which demonstrated that H2O2 can react with endogenous metal ions to form 
.OH via
the Fenton reaction (Rojanasakul et al., 1993).  It is interesting to note that when IL-10 was
added to a chemical system (Fenton Reaction), it did not inhibit .OH generation.  These
results suggest that IL-10 is not a free radical scavenger.  Instead, it interacts with the
cellular machinery in such a way that free radical production is inhibited.
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IV.5. DISCUSSION
IL-10 is an anti-inflammatory cytokine that plays an important regulatory role in
inflammatory diseases (Moore et al., 1993; de Vries, 1995).  Studies with IL-10 knockout
mice have shown that a key function of IL-10 is the control of inflammatory responses (Kuhn
et al., 1993).  In vitro and in vivo studies suggest that IL-10 could be a potentially useful
therapeutic agent for the treatment of acute and chronic, systemic and localized
inflammatory reactions.
Although numerous studies have been performed to identify the signaling pathways
targeted to by IL-10, the mechanism is still not completely understood.  We hypothesized
that IL-10 mediates part of its inhibitory effects via its effect on ROS.  Our studies show that
IL-10 pretreatment inhibits TNFα production of stimulated macrophages due to its ability to
decrease NF-κB DNA binding and NF-κB induced transcription.  Further analysis showed
that IL-10 inhibits LPS-induced IκBα degradation.
Macrophages provide an important line of host defense against noxious substances.
One of the essential mechanisms by which this is accomplished is the production of reactive
oxygen metabolites such as superoxide anion and hydrogen peroxide through the
respiratory burst.  Excessive production of these oxidative species, however, can also cause
toxic reactions to the cell and potentiate several pathologic conditions.  It has been
suggested that the highly reactive hydroxyl radical (.OH) which is generated from H2O2 via
the Fenton or Fenton-like reactions, is the major oxidant species that causes cellular injury
(Rojanasakul et al., 1993). Hydroxyl radicals are known to induce lipid peroxidation which
causes damage to the cell membrane.
NF-κB inducers produce ROS (Baeuerle and Henkel, 1994) and the observation that
antioxidants and radical scavengers inhibit the activation of NF-κB, strongly supports the
idea that oxygen radicals are involved in the release of IκBα from the NF-κB-IκB complex.
Recent studies have indicated that ROS can activate a number of cytokine genes including
the TNFα gene.  It has also been speculated that the protease activities involved with IκBα
are under the control of the cell’s redox status (Baeuerle and Henkel, 1994).  This
speculation is strengthened by the observation that the antioxidant PDTC prevents inducible
decay of IκBα in response to PMA (Beg et al., 1993; Henkel et al., 1993; Sun et al., 1993).
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Oxygen free radicals are known to facilitate the progress of inflammatory reactions.
Since NF-κB has been identified as an oxidative stress-responsive transcription factor that is
activated by a diverse range of inducers, it has been postulated that ROS may be the
common messenger involved in the signal transduction pathway leading to NF-κB activation
(Baeuerle and Henkel, 1994).  Our results show that ROS are involved in NF-κB activation
and IκBα degradation.  Specifically, .OH seems to be the key player in ROS mediated IκBα
degradation.  .OH radicals in macrophages are generated via metal-catalyzed Fenton
reaction [Mn+ + H2O2 -> M
(n+1)+ + OH- + .OH] using H2O2 as the source (Rojanasakul et al.,
1993).  These results are consistent with those observed by Schreck et al. (1992).  They
observed that H2O2 on its own does not activate the purified NF-κB-IκB complex and
therefore it appears that a metabolite of H2O2 caused the release of IκBα.  This metabolite is
probably the .OH radical.
Since IL-10 inhibits IκBα degradation, we tested the effect of IL-10 on .OH radical
generation.  IL-10 inhibits LPS-induced .OH radical generation as demonstrated by ESR.
The fact that IL-10 does not inhibit .OH radicals in a chemical system suggests that IL-10
does not act as free radical scavenger.  Instead it probably induces signals that interface
with the cellular signals that generate ROS in response to LPS-stimulation.  A recent study
by Schottelius et al. (1999) has shown that IL-10 inhibits TNFα-induced activation of IKK
which is responsible for phosphorylation and subsequent degradation of IκBα.  Bonizzi et al.
(2000) have suggested that ROS generation may be required for cell-specific kinase activity.
Based on our results and those reported earlier, we propose the following mechanism of
action for IL-10.  IL-10 inhibits ROS production which in turn inhibits IKK activity and hence,
IκBα degradation.  This results in a decrease in NF-κB activity and hence, decreases the
expression of inflammatory cytokines such as TNFα.  This whole cascade of events is
responsible for the anti-inflammatory properties of IL-10 in macrophages.
In conclusion, IL-10 inactivates macrophage production of reactive oxygen radicals,
thereby decreasing inflammation.  The results in this study provide a new light into the
action of IL-10.  Finally, the mechanism of IL-10 in this cell type may not be reflective of its
action in other cell types.  As rightly discussed by Bowie et al. (2000), signal transduction
pathways in different cell types need to be addressed individually.
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IV. 6. FIGURES
Fig. 1.  Inhibition of TNFα Production by IL-10.  (A) RAW 264.7 cells (106/ml) were
pretreated with varying concentrations of rmIL-10 (1-50 ng/ml) for 2 h at 37oC, after which
they were treated with LPS (0.1 µg/ml) for 6 h at 37oC.  The supernatants were collected at
the end of 6 h and assayed for TNFα by ELISA.  (B) Two stable cell lines were generated.
RAW IL-10 was stably transfected with IL-10-containing plasmid and RAW control was
transfected with control plasmid.  The cells (106/ml) were stimulated with LPS (0.1 µg/ml) for
6 h at 37oC after which the supernatants were collected and assayed for TNFα by ELISA.  *
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Fig. 2.  EMSA Studies of NF-κB Binding Activity in LPS-Treated Macrophages.  DNA
binding activity of NF-κB was determined using the nuclear extract of macrophages treated
with LPS (0.1 µg/ml) for 1 h at 37oC.  Lane 1: RAW 264.7 with no LPS, Lane 2: RAW 264.7
with LPS (0.1 µg/ml), Lane 3: RAW control with no LPS, Lane 4: RAW control with LPS (0.1
























































Fig. 3.  Effect of IL-10 on NF-κB-Dependent Gene Expression and IκBα Degradation.
(A) RAW 264.7 cells were transiently transfected with an expression plasmid containing
luciferase gene transcribed from the NF-κB-dependent promoter.  Thirty-six hours after
transfection, the cells were pretreated with varying concentrations of IL-10 (10-50 ng/ml)
before stimulation with LPS (0.1 µg/ml) for 12 h at 37oC.  Luciferase activity was then
measured by luminescence.  (B) Western blots were performed to determine effect of IL-10
on IκBα.  RAW control and RAW IL-10 cells (106/ml) were treated with LPS (0.1 µg/ml) for
the different time points and IκBα protein was measured by Western blots.  * indicates a
significant decrease from LPS-treated control (p<0.05).
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Fig. 4.  Effect of Oxygen Radical Scavengers on NF-κB-Dependent Gene Expression
and IκBα Degradation.  (A) RAW 264.7 cells were transiently transfected with an
expression plasmid containing luciferase gene transcribed from the NF-κB-dependent
promoter. Thirty-six hours after transfection, the cells were pretreated with the different
oxygen radical scavengers, SOD (500 U/ml), catalase (500 U/ml), and sodium formate (5
mM) for 4 h before stimulation with LPS (0.1 µg/ml) for 12 h at 37oC.  Luciferase activity was
then measured by luminescence.  (B) Western blots were performed to determine the effect
of ROS on IκBα.  RAW 264.7 cells (106/ml) were pretreated with the different ROS
scavengers, SOD (500 U/ml), catalase (500 U/ml), and sodium formate (5 mM) for 4 h
before stimulation with LPS (0.1 µg/ml) for the different time points.  * indicates a significant
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Fig. 5.  ESR Measurements of LPS-Induced ROS Generation.  (A) ESR spectrum
recorded 1 h after an addition of LPS (1 µg/ml) to macrophage RAW 264.7 cells (106/ml) in
the presence of spin trapper DMPO (100 mM).  (B) same as (A) but with no LPS treatment.
(C) same as (A) but with IL-10 (0.1 µg/ml) added.  (D) same as (A) but with catalase (500
U/ml) added.  (E) same as (A) but with sodium formate (5 mM) added.  The spectrometer
settings were as follows: receiver gain, 1.5x105; time constants 0.3 sec; modulation
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Toxicity Induced by Cationic Liposomes
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V.1. ABSTRACT
Cationic liposomes represent a class of nonviral vectors that hold great promise as
gene delivery vehicles.  However, recent studies have shown that they may be associated
with some toxicity.  The objectives of this study are to investigate the toxicity associated with
polycationic liposomes and to elucidate the underlying mechanism.  We tested the
hypothesis that the positive charge of liposomes is a key determinant of toxicity by testing
differently charged liposomes in mice. Differently charged liposomal systems including
cationic liposomes, LipofectAMINE and DOTAP, and neutral and negative liposomes were
evaluated for their toxicity after pulmonary administration in mice.  LDH assay and
differential cell counts were performed to measure toxicity and pulmonary inflammation,
respectively.  Reactive oxygen species (ROS) were assessed by luminol-dependent
chemiluminescence. Instillation of cationic liposomes elicited dose-dependent toxicity and
pulmonary inflammation.  This effect was more pronounced with the multivalent cationic
liposome LipofectAMINE as compared to the monovalent cationic DOTAP.  Neutral and
negative liposomes did not exhibit lung toxicity.  Toxicity associated with cationic liposomes
correlated with the oxidative burst induced by the liposomes.  LipofectAMINE induced a
dose-dependent increase in zymosan-stimulated production of ROS.  This effect was less
pronounced with DOTAP and absent with neutral and negative liposomes. ROS play a key
role in cationic lipid-mediated toxicity.  Polyvalent cationic liposomes cause a release of
ROS which are responsible for the pulmonary toxicity.
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 V.2. INTRODUCTION
With our increasing knowledge of human inherited and acquired diseases at a
molecular level, the use of gene therapy to restore a missing function or to treat certain
diseases has become a clinical reality.  Currently, however, the rate-limiting step in its
successful application is the development of safe and efficient gene delivery vehicles.
Vectors proposed for gene delivery fall into two categories, viral and nonviral.  Viral vectors
have achieved best results as far as transfection efficiency is concerned.  However, the
safety concerns and the immunological profile of viral vectors have steered research
towards the development of efficient non-viral carriers. Cationic lipids represent a class of
nonviral vectors that have shown the greatest success and promise so far.  Their lack of
immunogenicity, simplicity and ease of production make them attractive vectors for gene
therapy (Gao and Huang, 1995).  Cationic liposomes have been reported to successfully
transfect genes both in vitro (Behr et al., 1989; Felgner and Holm, 1989; Gao and Huang,
1991; Lee et al., 1996) and in vivo (Brigham et al., 1989; Lee et al., 1996).  Cationic lipid
based gene delivery protocols have also been used in clinical trials (Caplen et al., 1995;
Chadwick et al., 1997; Nabel et al., 1993).  However, their relatively low transfection
efficiency compared to that of the viral vectors makes them far from ideal.
Another concern regarding the use of cationic liposomes is their toxicity.  Cationic
lipids were considered to be safe initially, however, increasing evidence has suggested that
they may cause some toxic effects in vivo (Freimark et al., 1998; Scheule et al., 1997; Song
et al., 1997).  Experimental data indicate that in vivo toxicity does not correlate well with in
vitro toxicity.  In general, cationic liposomes are better tolerated in vitro suggesting that other
factors involved in vivo are responsible for the toxicity.  Scheule et al. (1997) have shown
significant lung toxicity following a nasal instillation of up to 300 nmol of lipid complexed with
400 nmol of pDNA.  They observed a dose-dependent lung inflammation associated with the
cationic lipid.  Song et al. (1997) have demonstrated acute toxicity at high positive charge
ratios of cationic lipid to plasmid DNA.  Freimark et al. (1998) reported that intratracheal
instillation of lipid alone or plasmid/lipid complex induced cytokine production and cellular
influx in the lung airway.  We have also found in this study that cationic liposomes cause an
inflammatory response in a dose-dependent manner when administered intratracheally.
This inflammation is seen as early as 6 h after instillation.
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The mechanism by which cationic liposomes facilitate gene transfection is still not
completely understood.  Since biological membranes are negatively charged, it has been
suggested that liposomes interact with cells through a nonspecific charge interaction.
Cationic liposomes form complexes with DNA through electrostatic interactions. The excess
positive charge of the complexes allows non-specific interactions with cell membranes.  This
property which results in efficient transfection, may be also responsible for causing cellular
toxicity.  Cationic lipids are also excellent surfactants with a potential of causing membrane
solubilization, poration, and lysis.  They can also change the membrane properties by
interacting with membrane proteins such as protein kinase C (Bottega and Epand, 1992)
which play an important role in signal transduction and gene regulation.
The origin of toxicity caused by cationic liposomes is not well understood.  We
hypothesized that the positive charge of liposomes plays an important role in lung toxicity.
Using differently charged liposomes, we found that the multivalent cationic liposome
LipofectAMINE was much more toxic than the monovalent cationic liposome DOTAP, and
that neutral and negative liposomes were not toxic at the relevant concentrations.
ROS have been identified as key mediators of pulmonary damage induced by
various stimuli (Janssen et al., 1993; Gossart et al., 1996).  To further identify the cause of
toxicity, we studied the effect of different liposomes on free radical generation.  We
observed that the highly charged cationic liposome LipofectAMINE caused a marked
inflammatory response as determined by neutrophil influx and oxidative burst of lung
lavaged cells.  This effect is charge related and can be reversed by pretreatment of mice
with the free radical scavenger N-ter-butyl-α-phenylnitrone (PBN).  Hence, our results




Healthy male Balb/c mice, 4-6 weeks old, were obtained from Jackson Laboratories
(Bar Harbor, ME).  They were acclimated in an AAALAC-approved facility for at least a week
before use.  The mice were fed food and water ad libitum.  Intratracheal instillations into
mice were performed by anesthetizing them with a mixture of ketamine and xylazine (45 and
8 mg/kg, i.p., respectively) and challenged by aspiration.  The animals were placed on a
board in a supine position.  The animal's tongue was extended with lined forceps and 50-
100 l of the test solution was placed on the back of the tongue.
Liposomes
Cationic liposomes used in this study were LipofectAMINE (Gibco BRL,
Gaithersburg, MD) and DOTAP (Boehringer Mannheim, Indianapolis, IN).  LipofectAMINE is
a 3:1 mixture of cationic lipid DOSPA and neutral lipid DOPE.  The neutral liposome used in
this study was palmitoyl-oleoyl phosphatidylcholine (POPC) (Sigma, St. Louis, MO) and the
negative liposome was a mixture of palmitoyl-oleoyl phosphatidylcholine (POPC) and
dioleoyl phosphatidylglcyerol (DOPG) (Sigma).  The neutral and negative liposomes were
reconstituted in sterile water according the manufacturer's instructions.  The neutral and
negative liposomes were extruded through polycarbonate membranes to achieve the same
size as that of LipofectAMINE and DOTAP.  Briefly, the lipid solution was briefly vortexed,
followed by incubation at 50oC for 10 min and then sequentially extruded through
polycarbonate membranes with the following pore sizes: 1.0, 0.6 and 0.2 m.  The size of
the liposomes were measured by dynamic laser scattering using Coulter N4SD particle sizer
(Hialeah, FL, USA).  The mean particle size of different liposomes are as follows:
LipofectAMINE, 160 nm; DOTAP, 189 nm; neutral, 171 nm; and negative, 174 nm.
Bronchoalveolar Lavage
At selected time intervals, treated mice were euthanized with an intraperitoneal
injection of 0.25 mL sodium pentobarbital (EUTHA-6, Western Medical Supply Inc., Arxadia,
CA). A tracheal canula was inserted and the lungs were lavaged through the canula using
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ice-cold PBS.  Five lavages of 0.8 ml each were collected. The first lavage was separated
from the consecutive lavages.  Bronchoalveolar lavage cells (BALC) were isolated by
centrifugation (500g, 10 min, 4oC). The cell free supernatants were collected and used for
biochemical measurements.  For each animal, the cell pellet was resuspended in 1 mL of
HEPES buffer (10 mM N-2-hydroxyethylpiperazine-N'-1-ethanesulfonic acid, 145 mM NaCl,
5.0 mM KCl, 1.0 mM CaCl2, 5.5 mM D-glucose; pH 7.4), centrifuged (500g, 10 min, 4
oC),
and the supernatant was decanted and discarded.  The BALC pellet was then resuspended
in 1 mL HEPES buffer and placed on ice. Cell counts and differentials were determined
using a Coulter Multisizer II and AccuComp software (Coulter Electronics, Hialeah, FL).
LDH Activity
Lactate dehydrogenase (LDH) assay was performed to assess the effect of
liposomes on cellular toxicity. Mice were instilled with the test agents. After the treatments,
bronchoalveolar lavage was performed and the supernatant from the first lavage was
assayed for LDH activity. LDH activity was determined by monitoring the oxidation of
pyruvate coupled with the reduction of NAD at 340 nm using an LDH assay kit (Roche
Diagnostic Systems, Montclair, NJ). The assay was performed on Cobas Fara II Analyzer
(Roche Diagnostic Systems). One unit per liter of LDH activity is defined as the amount of
enzyme that converts 1 µmol of lactate to 1 µmol of pyruvate with the concomitant reduction
of 1 µmol of NAD to 1 µmol of NADH per minute per liter of sample in the assay procedure.
Administration of PBN
For this procedure, the spin trapping agent, PBN, was administered in vivo by i.p.
injection at a dose of 300 mg/kg, 20 min before instillation of liposomes after dissolving it in
PBS.
Chemiluminescence
Chemiluminescence (CL) assay of bronchoalveolar lavage cells (BALC) was
conducted in a total volume of 0.25 mL HEPES buffer. Resting BALC CL was determined by
incubating 0.25x106 BALC at 37oC for 5 min with 0.04% (w/v) luminol (Sigma) followed by
the measurement of CL for 15 min. To determine zymosan-stimulated BALC CL, the assay
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was modified to include 1 mg unopsonized zymosan  (Sigma), which was added to the
assay immediately prior to measurement of CL. CL measurement was conducted with an
automated luminometer (Berthold Autolumat LB 953, Wallace, Inc., Gaithersburg, MD) at
390-620 nm for 15 min and the integral of counts per minute (cpm) versus time calculated.
Zymosan-stimulated CL was calculated as the cpm in the zymosan-stimulated assay minus
the cpm in the resting assay.
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V.4. RESULTS
Charge Dependent Toxicity of Liposomes
To test the hypothesis that the charge of the liposome is responsible for toxicity, we
tested differently charged liposomes on lung inflammation and damage.  Cationic liposomes
used in this study were LipofectAMINE and DOTAP.  LipofectAMINE is a commercially
available liposome that has been successfully used in vitro (Hawley-Nelson et al., 1993).  In
our experience, we have found that LipofectAMINE is superior to most other commercially
available liposomes for in vitro gene transfection of lung cells.  The cationic lipid present in
LipofectAMINE has 4 protonatable amines on its headgroup at physiological pH.  DOTAP is
a monovalent cationic lipid.  The neutral liposome used in this study is phosphatidylcholine
and the negative liposome is a mixture of phosphatidylcholine and phosphatidylglycerol.
Intratracheal instillations of differently charged liposomes were performed in mice
lungs.  One day after instillation, mice were lavaged and bronchoalveolar lavage fluid
(BALF) was tested for LDH activity and cell counts.  LDH activity is a measure of toxicity.
Inflammation is characterized by an increase in polymorphonuclear leukocytes (PMN) and
hence, the cell counts are an indication of inflammation.  There was a charge dependent
toxicity of liposomes as determined by LDH (Fig. 1A).  For a fair comparison, the dose of all
liposomes was fixed at a dose that is commonly used in gene transfection protocols in vivo
(Liu et al., 1999).  The polycationic LipofectAMINE was found to be most toxic, followed by
DOTAP, which is monocationic.  Neutral and anionic liposomes did not exhibit significant
toxicity over PBS control.  This toxicity correlated with the inflammation induced.
LipofectAMINE-induced inflammation, as determined by PMN count, was greater than that
induced by other liposomes (Fig. 1B).  Further studies have shown that there is a dose
dependent increase in toxicity (Fig. 2A), as well as in the induction of inflammation (Fig. 2B)
associated with instillation of LipofectAMINE.  These results suggest that toxicity of
liposomes is dependent on the charge of the liposome and that toxicity is seen only with
cationic liposomes.
The positively charged headgroup of the liposome is responsible for its cationic
nature.  To identify whether this component of the cationic liposome is responsible for the
observed toxicity, we instilled mice with relevant concentrations of spermine.  Spermine is
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the headgroup of the cationic lipid present in LipofectAMINE.  However, administration of
spermine elicited neither a toxicity (Fig. 3A) nor an inflammatory response (Fig. 3B) in
comparison to the administration of equivalent dose of cationic liposome.  These results
suggest that both the cationic headgroup and lipophilic tail of the liposome are required for
toxicity induction, presumably through its surfactant action.
Oxygen Radical-Mediated Toxicity of Cationic Liposomes
ROS have been identified as key mediators of pulmonary damage (Gossart et al.,
1996; Janssen et al., 1993).  We hypothesized that the cationic liposome mediated toxicity
was in part due to the production of ROS by lung cells.  To study the effect of liposomal
charge on ROS production, we instilled mice with differently charged liposomes and lavaged
the animals 24 h after instillation.  The lavaged cells were then tested for their basal and
zymosan-induced oxidative burst.  Consistent with our toxicity data, we observed that
cationic liposomes triggered an oxidative burst (Fig. 4A).  Neutral and negative liposomes
did not exhibit a zymosan-induced CL response.  Multivalently charged cationic liposome,
LipofectAMINE, showed a greater induction of ROS than the monovalently charged DOTAP.
LipofectAMINE-induced ROS production was found to be dose dependent (Fig. 4B).
Stimulation of lavaged cells with zymosan in cationic liposome-instilled mice resulted in
about 25-100 times enhancement of zymosan-triggered peak CL intensity over the controls.
The role of ROS in cationic lipid-mediated toxicity was further studied by
administering a free radical trapper, PBN.  PBN has been used in previous studies as a spin
trap for ROS (Gossart et al., 1996).  It would be reasonable to assume that if oxygen
radicals produced by LipofectAMINE are responsible for the toxicity, then scavenging these
radicals would reverse the toxicity.  To test this hypothesis, we pretreated the mice with PBN
(i.p., 300mg/kg) 20 min before liposomal instillation.  One day after instillation, mice trachea
were lavaged and the lavaged cells were tested for oxidative burst, toxicity and
inflammation.  As can be seen in Fig. 5A, PBN decreases oxidative burst induced by
liposome treatment.  PBN by itself does not cause any production of ROS.  It also
decreases the toxicity (Fig. 5B) and inflammation (Fig. 5C) induced by LipofectAMINE.
These results support the role of ROS in LipofectAMINE-mediated lung toxicity.
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V.5. DISCUSSION
Cationic lipids have been used successfully in both in vitro and in vivo gene transfer
(Behr et al., 1989; Brigham et al., 1989; Felgner and Holm, 1989; Gao and Huang, 1991;
Lee et al., 1996).  However, there have been some recent reports of toxicity associated with
their use in vivo (Freimark et al., 1998; Scheule et al., 1997).  The principle objective of this
study is to understand the influence of charge of the liposome on its in vivo toxicity profile.
We have tested the toxicity of differently charged liposomes in vivo in mice.  This study has
revealed four significant observations: (1) charge of liposome is a key determinant of
toxicity; (2) cationic liposomes are more toxic than neutral/negative liposomes and
multivalent cationic liposomes are more toxic than monovalent cationic liposomes; (3) the
cationic headgroup of liposome by itself is not toxic but its presence in the cationic liposome
causes toxicity; and (4) ROS are responsible for cationic liposome-mediated toxicity.
Cationic lipids are composed of a hydrophilic anchor connected via a linker to a
positively charged headgroup (Gao and Huang, 1991; Gao and Huang, 1995).  It has been
shown that although all components of the cationic lipid contribute to its transfection
efficiency, the nature of the headgroup plays a major role in transfection efficiency of the
lipid.  The positively charged headgroup of most cationic lipids consists of one or more
amine groups with various degrees of substitution.  This domain facilitates both electrostatic
interactions with negatively charged DNA to form the lipoplex as well as interactions with
target cells.  Polyvalent headgroups have been reported to be superior to their monovalent
counterparts due to their capacity for greater DNA compaction (Behr et al., 1989; Hawley-
Nelson et al., 1993; Remy et al., 1994) and non-specific cell interactions.  However, for the
same reason, they are also toxic.  We and others (Freimark et al., 1998; Scheule et al.,
1997) have observed that direct instillation of cationic lipid into the lungs elicits an
inflammatory response which is dose-dependent.  Forming a complex with plasmid DNA did
not decrease the toxicity even when the net charge of pDNA/lipid complexes was neutral.
The mechanism of toxicity of cationic liposomes has not been well characterized.  It
has been suggested that the amphipathic nature of cationic lipid is responsible for toxicity
because they are excellent detergents.  This hypothesis is supported by our results.
Spermine, the headgroup of lipid responsible for the positive charge, is not toxic by itself at
the relevant concentrations.  Scheule et al. (Scheule et al., 1997) have suggested that
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introducing a larger headgroup increases water solubility resulting in a greater tendency to
form micelles and hence, a potential for greater toxicity.
Cationic liposomes have been associated in the induction of cytokines (Freimark et
al., 1998), cellular influx and pulmonary inflammation (Scheule et al., 1997).  Inflammation is
characterized and triggered by several mediators, especially those produced by
macrophages such as cytokines and ROS.  Positively charged liposomes caused an
increase in inflammatory cells which are responsible for the release of inflammatory
mediators such as cytokines and ROS.  We assessed ROS production by luminol
dependent CL (Antonini et al., 1994).  This method allowed measurement of the cellular and
tissue events related to the oxidative process.  We have shown that treatment with positively
charged liposomes increased the ability of lung cells to release ROS in response to various
stimuli such as zymosan.
To confirm the role of ROS in the development of pulmonary inflammation and
toxicity, we used the spin trapping agent PBN.  PBN has been shown to reduce endotoxin-
induced rat mortality through its ability to trap intermediate oxygen and carbon-centered
radicals (Pogrebniak et al., 1992).  We have shown here that in vivo pretreatment with PBN
decreases the ability of lung cells to release ROS in response to stimuli.  This pretreatment
also decreased pulmonary inflammation and toxicity induced by cationic liposomes.
We report here, for the first time, the role of ROS in cationic lipid mediated toxicity.
The data presented here suggest that cationic liposomes cause inflammation and toxicity via




Fig. 1.  Comparison of Toxicity Induced by Differently Charged Liposomes.
Intratracheal instillations were performed on mice with LipofectAMINE, DOTAP, neutral and
negative liposomes at a fixed dose of 200 nmol/mouse.  Bronchoalveolar lavage was
performed 24 h after instillation.  The BAL was tested for (A) LDH activity and (B) PMN cell
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Fig. 2.  Dose-Dependent Toxicity Induced by LipofectAMINE.  Intratracheal instillations
were performed on mice with different concentrations of LipofectAMINE (0-200
nmol/mouse).  Bronchoalveolar lavage was performed 24 h after instillation.  The BAL was
tested for (A) LDH activity and (B) PMN cell count as described in the Methods section.  The
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Fig. 3.  Role of the Headgroup Spermine in LipofectAMINE-Induced Lung Toxicity.
Intratracheal instillations were performed on mice with spermine and LipofectAMINE (200
nmol/mouse).  Bronchoalveolar lavage was performed 24 h after instillation.  The BAL was
tested for (A) LDH activity and (B) cell count as described in the Methods section.  The
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Fig. 4.   (A) Comparison of ROS Production by Differently Charged Liposomes.  (B)
Dose-Dependent Induction of ROS by LipofectAMINE.   Intratracheal instillations were
performed on mice with LipofectAMINE, DOTAP, neutral and negative liposomes (200
nmol/mouse).  Bronchoalveolar lavage was performed 24 h after instillation.
Chemiluminescence assay was performed as described in the Methods section.  The values
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Fig. 5.  Effect of Pretreatment of Mice with PBN before Instillation with LipofectAMINE.
Mice were pretreated with free radical scavenger, PBN, (i.p., 300 mg/kg) 20 min before
intratracheal instillations with LipofectAMINE (200 nmol/mouse).  Bronchoalveolar lavage
was performed 24 h after instillation.  The BAL was tested for (A) chemiluminescence, (B)
LDH activity and (C) cell count as described in the Methods section.  The values are the
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Inhibition of Endotoxin-Induced Lung Inflammation
by Interleukin-10 Gene Transfer in Mice
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VI.1. ABSTRACT
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that has great potential to
be used for the treatment of inflammatory and immune illnesses.  Gene transfer
technology now permits directed expression of exogenous genes within specific organs
(e.g., lung) of intact animals. In the present study, gene transfer was used to induce IL-
10 transgene expression in mice lungs for a possible treatment of endotoxin-induced
lung inflammation.  Gene transfer was performed using CMV-IL-10 plasmid with the aid
of liposomal transfecting agents, LipofectAMINE and DOTAP.  Administration of
endotoxin caused a marked increase in lung inflammation as indicated by increased
tumor necrosis factor (TNF)-α release and neutrophil cell count.  Pretreatment of the
mice with IL-10 plasmid, either alone or in combination with LipofectAMINE, had no
inhibitory effect on lung inflammation and did not induce IL-10 protein expression.
LipofectAMINE by itself was found to be toxic and cause lung inflammation, the effect
that was not observed with DOTAP.  IL-10 plasmid, when co-delivered with DOTAP,
expressed biologically active IL-10 protein (150-700 pg/ml) and caused a reduction in
lung inflammation induced by endotoxin.  Maximum transgene expression was observed
when a dose of 12 nmol of DOTAP per µg DNA was used.  This expression was seen as
early as 3 h after administration, peaked at 12 h, and declined thereafter.  We conclude
that IL-10 gene transfer is a feasible approach for the treatment of lung inflammation.




IL-10 is an anti-inflammatory cytokine that is regularly produced during
inflammatory processes in vivo, usually by the same cells that release inflammatory
mediators (e.g., monocytes, macrophages, T cells).  It inhibits the production of
inflammatory cytokines, e.g., IL-1, IL-6, and TNF-α, by inflammatory cells stimulated with
endotoxin and interferon (Fiorentino et al., 1991). IL-10 has been implicated in a number
of inflammatory disorders such as sepsis, chronic arthritis, and inflammatory bowel
diseases (Goldman et al., 1996; Moore et al., 1993).  In animal models of sepsis, IL-10,
given before or soon after Gram-negative bacterial endotoxin reduces TNF-α production,
hypothermia, and death (Howard et al., 1993; Kuhn et al., 1993).  It was found that mice
are more sensitive to LPS-induced shock by treatment with anti-IL-10 antibodies (Ishida
et al., 1994).  It was also found that IL-10 deficient mice developed severe enterocolitis
and that IL-10 is an essential immunoregulator in the intestinal tract (Kuhn et al., 1993).
In an experimental model of lung inflammation, IL-10 has been shown to inhibit lung
inflammation induced by IgG immune complexes (Lentsch et al., 1997; Mulligan et al.,
1993).  Because of its potent anti-inflammatory effects, IL-10 has been investigated as a
potential therapeutic agent for inflammatory disorders.
Most IL-10 studies to date have been carried out using recombinant IL-10 protein
(Howard et al., 1993; Kuhn et al., 1993; Mulligan et al., 1993; Tumpey et al., 1994; Kuhn
et al., 1993; Mulligan et al., 1993; Tumpey et al., 1994).  However, recombinant protein
has the disadvantage of being short-lived, poorly accessible to tissue interstitium, and
expensive.  In the present study, we propose to use gene transfer strategy to deliver the
therapeutic IL-10 gene to the lung for the possible treatment of lung inflammation.  Gene
transfer technology offers the potential advantage of prolonged expression.  In addition,
because of the amplification process associated with gene expression, i.e., a single
gene copy can express numerous copies of protein, this method is therefore potentially
more effective than the protein delivery method.  However, the use of gene transfer
method has been hindered by inefficient gene expression in vivo.  The present study
investigated the effect of naked DNA and various DNA-liposome complexes on IL-10
gene expression.  The specific aims of this study are 1) to determine whether IL-10 gene
transfer can be used to produce therapeutically relevant levels of IL-10 protein in mice
lungs, 2) to determine whether the transgene expression can result in reduced lung
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inflammation caused by endotoxin, 3) to evaluate the efficacy and safety of gene
delivery systems in transferring the IL-10 gene to lung cells.
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VI.3. MATERIALS AND METHODS
Animals
Healthy male Balb/c mice, 4-6 weeks old, were obtained from Jackson
Laboratories (Bar Harbor, ME).  They were acclimated in an AAALAC-approved facility
for at least a week before use.  The mice were fed food and water ad libitum.
Intratracheal instillations into mice were performed by anesthetizing them with a mixture
of ketamine and xylazine (45 and 8 mg/kg, i.p., respectively) and challenged by
aspiration.  The animals were placed on a board in a supine position.  The animal's
tongue was extended with lined forceps and 50-100 µl of the test solution was placed on
the back of the tongue.
 Preparation of Liposome-DNA Complexes
Plasmid CMV-mIL-10, which contains mIL-10 cDNA driven by a cytomegalovirus
immediate-early promoter, was amplified in DH5α strain of E. coli and isolated and
purified according to the manufacturer’s instructions (Qiagen, Chatsworth, CA).
Endotoxin-free plasmid was used for all experiments.  Cationic liposomes used in this
study were LipofectAMINE (Gibco BRL, Gaithersburg, MD) and DOTAP (Boehringer
Mannheim, Indianapolis, IN).   For the preparation of DNA-liposome complexes, an
indicated amount of LipofectAMINE or DOTAP was added to the diluted DNA in distilled
water and the mixture was incubated for 10 min before use.
Bronchoalveolar Lavage
At selected time intervals, treated mice were euthanized with an intraperitoneal
injection of 0.25 ml sodium pentobarbital (EUTHA-6, Western Medical Supply Inc.,
Arxadia, CA).  A tracheal canula was inserted and the lungs were lavaged through the
canula using ice-cold PBS.  Five lavages of 0.8 ml each were collected.  The first lavage
was separated from the consecutive lavages.  Bronchoalveolar lavage cells (BALC)
were isolated by centrifugation (500g, 10 min, 4oC).  The cell-free supernatants were
collected and used for biochemical measurements.  For each animal, the cell pellet was
resuspended in 1 ml of HEPES buffer (10 mM N-2-hydroxyethylpiperazine-N'-1-
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ethanesulfonic acid, 145 mM NaCl, 5.0 mM KCl, 1.0 mM CaCl2, 5.5 mM D-glucose; pH
7.4), centrifuged (500g, 10 min, 4oC), and the supernatant was decanted and discarded.
The BALC pellet was then resuspended in 1 ml HEPES buffer and placed on ice.   Cell
counts and differentials were determined using a Coulter Multisizer II and AccuComp
software (Coulter Electronics, Hialeah, FL).
LDH Activity
Lactate dehydrogenase (LDH) assay was performed to assess the effect of
liposomes on cellular toxicity.   Mice were instilled with the test agents.  After the
treatments, bronchoalveolar lavage was performed and the supernatant from the first
lavage was assayed for LDH activity.   LDH activity was determined by monitoring the
oxidation of pyruvate coupled with the reduction of NAD at 340 nm using an LDH assay
kit (Roche Diagnostic Systems, Montclair, NJ).  The assay was performed on Cobas
Fara II Analyzer (Roche Diagnostic Systems).  One unit per liter of LDH activity is
defined as the amount of enzyme that converts 1 µmol of lactate to 1 µmol of pyruvate
with the concomitant reduction of 1 µmol of NAD to 1 µmol of NADH per minute per liter
of sample in the assay procedure.
Cytokine Determination
Supernatants from the first bronchoalveolar lavage were assayed for cytokines
using enzyme-linked immunosorbent assay (ELISA) kits specific for murine TNF-α or IL-
10 according to the manufacture’s instructions (Endogen).  The sensitivity of the assays




Endotoxin-Induced Lung Inflammation and its Inhibition by IL-10 Protein
Endotoxin-induced lung inflammation is associated with increased production of
TNF-α and sequestered pulmonary neutrophils (Chang, 1994; Cirelli et al., 1995).  In the
present study, we utilized these two indices of inflammation as quantitative measures of
lung inflammation.  Lung inflammation was induced by an intratracheal instillation of LPS
(30 µg/mouse) into mice lungs.  At various time points after the instillation, TNF-α level
and PMN cell count were measured.  Fig. 1A shows that LPS stimulation caused a rapid
but transient increase in TNF-α production.  This increase in cytokine level occurred
within an hour of stimulation and reached a maximum at 6 h.  By 24 h, the TNF-α level
already subsided.  Fig. 1B shows that PMN cell count also increased in response to LPS
stimulation.  This effect was time-dependent and more sustained than the TNF-α level.
To study the effect of IL-10 gene transfer on lung inflammation, it is first
necessary to test the anti-inflammatory effect of IL-10 protein in our lung inflammation
model.  Mice were pretreated with varying amounts of purified recombinant IL-10 (0-100
ng/mouse) 2 h before instillation with LPS (30 µg/mouse).  Six hours after LPS
treatment, the mice were lavaged and the BALF was assayed for TNF-α level and PMN
cell count.  Figs. 2A and 2B show that rIL-10 effectively inhibited LPS-induced TNF-α
production and PMN count in a dose-dependent manner.  Maximum inhibitory effects
were observed at the rIL-10 dose of 50 ng/mouse.  Increasing the dose of IL-10 beyond
this point did not result in further inhibition of TNF-α level and PMN count.  Thus, our
results indicate that IL-10 protein is indeed a potent anti-inflammatory molecule in vivo.
IL-10 Gene Transfer and the Delivery System
Studies by Meyer et al. (1995) have shown that naked CMV-CAT plasmid when
instilled intratracheally, expresses CAT protein in mice lungs.  To test if naked DNA by
itself can express IL-10 in the lungs, IL-10 plasmid was instilled and BALF was analyzed
for IL-10 protein levels at different time points.  Introduction of naked IL-10 plasmid (10-
300 µg/mouse) did not lead to any detectable expression of IL-10 protein in the BALF.
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Because our subsequent studies show that only 10 µg of the plasmid was sufficient to
induce IL-10 protein expression when an appropriate delivery system was used, we
therefore concluded that naked IL-10 DNA by itself was ineffective and that there is a
need for a delivery system for efficient gene transfection in vivo.
In a separate study, we have found that LipofectAMINE, a widely used
transfecting agent, is one of the most effective agents in transfecting lung cells in vitro.
Therefore, we attempted to use this agent to aid the transfection of IL-10 plasmid in vivo.
Varying amounts of LipofectAMINE (20-100 nmol/mouse) were instilled with the plasmid
DNA (10 µg/mouse) into mice lungs. Twelve hours after the treatment, the BALF was
collected and analyzed for IL-10 protein, PMN cell count, and LDH activity.  Our BALF
analysis showed that there was no IL-10 expression (data not shown).  Moreover, the
PMN count was very high in mice treated with DNA-LipofectAMINE complex or
LipofectAMINE alone (Fig. 3A).  The measurement of LDH activity, which was used as
an indication of lung toxicity, also showed that LipofectAMINE was very toxic at the
concentrations used (Fig. 3B).
Since LipofectAMINE is very toxic by itself, we can not use this liposome to
enhance DNA delivery.  Further studies on the in vivo toxicity of cationic liposomes by
our group (Dokka et al., 2000) revealed that LipofectAMINE due to its polycationic nature
caused a release of highly reactive oxygen species by lung cells which is responsible for
lung toxicity.  To avoid this problem, a monovalent cationic liposome, DOTAP, was used
to aid the delivery of DNA.  DOTAP has been used as a gene delivery system in a
number of in vivo applications (McLachlan et al., 1995; McLachlan et al., 1996; Porteous
et al., 1997).  Our results show that DOTAP was relatively non-toxic and was effective in
promoting IL-10 gene expression in the lungs (see below).
Optimization of Gene Delivery using DOTAP
To optimize IL-10 gene transfer in the lung using DOTAP, we tested different
DNA:DOTAP ratios on IL-10 gene expression (Fig. 4).  As controls, animals were
instilled with DOTAP alone or with free DNA alone.  As might be expected, no transgene
expression was observed in animals that received only DOTAP or DNA alone.  Co-
instillation of the DNA and DOTAP resulted in a dose-dependent expression of IL-10 in
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the mice lungs (Fig. 4A).  Maximum expression was obtained when 12 nmol of DOTAP
per µg DNA was used.  Beyond this ratio, the expression dropped significantly.  PMN
data showed that DOTAP, unlike LipofectAMINE, did not cause any significant effect on
lung inflammation (Fig. 4B).  Similarly, LDH data indicated that DOTAP was non-toxic
except when the highest concentration (150 nmol/mouse) was used (Fig. 4C).  Because
at this concentration the level of IL-10 expression also decreased, it is therefore likely
that the decreased expression may be a result of toxicity associated with high-
concentration DOTAP.  The kinetics of IL-10 expression following DNA-DOTAP
administration was also studied (Fig. 5).  IL-10 expression was seen to peak at 12 h after
instillation and subsided by 24 h.
Effect of IL-10 Gene Transfer on LPS-Induced Lung Inflammation
Since we developed a delivery system capable of expressing IL-10 in the lung,
the next step was to study the functional effect of this expressed IL-10 on LPS-induced
lung inflammation.  Mice were instilled with IL-10-DNA/DOTAP complexes 12 h prior to
LPS stimulation.  Six hours after LPS stimulation, mice were sacrificed and BALF was
tested for PMN count, IL-10 and TNF-α levels.  As seen in Fig. 6A, DNA:DOTAP
complexes when delivered either with or without LPS, expressed a high level of IL-10
protein.  LPS by itself induced a modest but significant amount of IL-10 (Fig. 6A).  At the
dose of 30 µg/mouse, LPS caused a dramatic increase in TNF-α production which was
decreased (~3-fold) by IL-10 gene expression (Fig. 6B).  LPS (10 µg/mouse) caused a
lower TNF-α response which was completely inhibited by IL-10 gene expression (Fig.
6B).  Treatment of the mice with DNA/DOTAP complexes similarly inhibited LPS-induced
PMN cell count (Fig. 6C).  Thus, our results indicate that the gene delivery system was




IL-10 is a potent anti-inflammatory cytokine, which regulates the function of
various cell types of the immune system (Moore et al., 1993). Its anti-inflammatory
properties have been established in a number of in vivo models including sepsis,
enterocolitis, and immune complex- or allergan-induced inflammation (Howard et al.,
1993; Kuhn et al., 1993; Lentsch et al., 1997; Mulligan et al., 1993; Tumpey et al., 1994).
Most of the in vivo studies to date have been carried out by using recombinant IL-10
protein (Howard et al., 1993; Kuhn et al., 1993; Lentsch et al., 1997; Mulligan et al.,
1993; Tumpey et al., 1994).  The present study investigated the feasibility of utilizing IL-
10 gene transfer for the treatment of lung inflammation. Gene transfer technology now
permits directed expression of exogenous genes within specific organs (e.g., lung) of
intact animals (Brigham et al., 1994).
There have been conflicting reports on the capability of naked DNA to express
proteins when administered to the lung (Felgner and Holm, 1989; Li and Huang, 1997;
Meyer et al., 1995).  Meyer et al. (1995) have shown that transgene expression from
naked DNA is as high as that seen when the DNA is co-administered with liposomes.
On the other hand, Li et al. (1997) have shown that naked DNA alone did not express
the gene in vivo.  To test if naked DNA is effective in our system, we instilled naked DNA
into mice lungs and tested for IL-10 gene expression.  Consistent with the results of Li et
al. (1997), we observed no gene expression with the naked DNA.  Thus, we concluded
that a delivery system is required for efficient IL-10 gene expression in the lung.
IL-10 gene transfer has been used with some success for the treatment of
rheumatoid arthritis (Ghivizzani et al., 1998; Whalen et al., 1999) and endotoxemia
(Drazan et al., 1996; Xing et al., 1997; Drazan et al., 1996; Whalen et al., 1999).
However, in all these studies replication-defective viral vectors were used as a delivery
system.  Viral vectors, although more efficient than non-viral systems, are considered to
be risky due to their potential for viral infection and immunogenicity.  These potential
deleterious side effects have steered gene transfer research toward developing non-viral
delivery systems. Cationic liposome technology has become well established for
introducing DNA into cells and these liposomes have been considered to be among the
most promising carriers for gene therapy (Gao and Huang, 1995).  In spite of the
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effectiveness of cationic liposomes in transfecting cells in vitro, their transfection
efficiency in vivo is still fairly low compared to that of the viral vectors (Lee et al., 1996).
DOTAP is a cationic liposome that has been used to transfect lung cells in vivo
(McLachlan et al., 1995; McLachlan et al., 1996; Porteous et al., 1997).  In our studies
we found DOTAP to be relatively non-toxic and hence we chose this liposomal system
for IL-10 gene transfer.
We have shown that it is possible to express IL-10 in the lung when delivered as
a DNA-liposome complex. The expressed IL-10 is capable of suppressing endotoxin-
induced lung inflammation. Since endotoxin-induced lung inflammatory injury is a
common cause of death in sepsis and respiratory distress syndrome, our findings
strongly suggest the therapeutic potential of IL-10 gene transfer for the protection of
endotoxic lung injury.  Nonetheless, the expression of DNA plasmid from our delivery
system is transitory and subsides by around 24 h.  These results are consistent with
those observed by Li et al. (1997).  They also observed that there was a rapid decline of
gene expression in vivo in the lungs.  They performed Southern blot analysis on DNA in
the lungs and could detect DNA till around 6 h, after which the level declined and was
barely detectable at 24 h (Li and Huang, 1997).  Meyer et al. (1995) also showed that
there was a reduction in intact DNA as early as 5 min after instillation to the lungs. They
concluded that DNA was rapidly eliminated from the lungs due to degradation since
short DNA fragments were observed at early times in Southern blots.
Both the groups reported that cationic liposomes increase the extent and
duration of plasmid DNA in the lungs (Li and Huang, 1997; Meyer et al., 1995).
Southern blot and PCR analysis demonstrated that rapid degradation of DNA is
significantly slowed in the presence of cationic liposomes.  Cationic liposomes assist in
retaining DNA molecules in the lung for a time sufficient for gene transfer to be complete
before they can be washed out of the capillary bed by normal blood flow.  Thus, it
appears that the retention time of the DNA molecules in the lung is likely to play a critical
role in determining the level of gene expression.  There could be a number of potential
causes for this rapid decline in DNA expression including A) loss of plasmid DNA from
the transfected cells, B) loss of transfected cells due to cell death, and C) loss of
transgene expression due to promoter shut-off.  Recently, it has been reported that the
CMV promoter is suppressed by interferon-γ (Harms and Splitter, 1995).  Interferon is
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one of the inflammatory cytokines that is released in response to LPS stimulation (Sing
et al., 2000).  Since the IL-10 plasmid used in this study contains CMV promoter, it is
possible that such inactivation may have caused a reduction in IL-10 expression.
We report here, for the first time, that intratracheal administration of
DNA/liposome complexes results in clinically relevant concentrations of IL-10 protein.
This IL-10 gene transfer can downregulate TNF-α expression and suppress lung
inflammation induced by LPS. One of the goals of gene therapy is to provide a
prolonged expression of therapeutic proteins over a period of time.  This would eliminate
the need for repeated administration of short-lived recombinant proteins. However, in our
system we have shown that while gene delivery of IL-10 does inhibit LPS-induced
inflammation, IL-10 expression does not last beyond 24 h.  While these results are
encouraging, it is clear that there are still many hurdles to overcome before liposome-
mediated gene transfer can be regarded as a viable therapy for lung inflammation.
Significant improvements in gene transfer efficiency and persistence of gene expression
need to be attained.  Development of better vectors would allow gene therapy to be a
clinical reality.
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VI.6. FIGURES
Fig. 1. LPS-Induced Lung Inflammation in Mice. Mice were instilled with LPS (0.03
mg/mouse) and bronchoalveolar lavage was performed 1, 3, 6, 24 and 48 h after
instillation. The BAL was tested for A) TNF-α concentration and B) PMN cell count.











































Fig. 2. Effect of Pretreatment of Mice with rIL-10 before instillation with LPS. Mice
were preinstilled with different amounts of rIL-10 (0-100 ng/mouse) 2 h before LPS
treatment (0.03 mg/mouse). Bronchoalveolar lavage was performed 6 h after instillation.
The BAL was tested for A) TNF-α concentration and B) PMN cell count. Values are















































Fig. 3. Delivery of IL-10 Plasmid with LipofectAMINE. Mice were instilled with DNA
(10 µg/mouse), DNA-LipofectAMINE complex (10 µg:60 nmol/mouse), or LipofectAMINE
alone (20, 60, 100 nmol/mouse). Bronchoalveolar lavage was performed 12 h after
instillation. The BAL was tested for A) PMN cell count and B) LDH activity. Values are




















































Fig. 4. Optimization of DNA-DOTAP Delivery System. Mice were instilled with DNA
(10 µg/mouse) or DNA-DOTAP complexes (10 µg:60-150 nmol/mouse). Twelve hours
after the instillation, bronchoalveolar lavage was performed and the BAL was tested for
A) IL-10 level, B) PMN cell count, and C) LDH activity. Values are means + SD; n = 4
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Fig. 5. Time Profile of IL-10 Expression Following DNA-DOTAP Administration.
Mice were instilled with DNA-DOTAP (10 µg:120 nmol/mouse). Bronchoalveolar lavage
was performed 3, 6, 8, 12, and 24 h after instillation, and the BAL was tested for IL-10




















Fig. 6. Effect of IL-10 Gene Transfer on LPS-Induced Lung Inflammation. Mice were
instilled with DNA-DOTAP (10 µg:120 nmol/mouse) 12 h  before intratracheal instillation
with LPS (10, 30 µg/mouse). Bronchoalveolar lavage was performed 6 h after LPS
instillation. The BAL was tested for A) IL-10 concentration, B) TNF-α concentration, and
C) PMN cell count. Values are means + SD; n = 4 mice/group. * p < 0.05 vs. untreated
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OVERALL CONCLUSIONS
1. Nuclear expression vectors were more effective at IL-10 expression than the
cytoplasmic vectors tested. Hence, the nuclear expression plasmids were chosen for
all further studies.
2. Macrophage transfection was maximal at the DNA:LipofectAMINE:protamine ratio of
1:12:1 µg/ml. This transfection method showed minimal toxicity at the concentrations
tested and was at least 20-25-fold superior to the most frequently used DEAE-
dextran method for macrophage transfection.
3. The presence of endotoxin in plasmid DNA preparations severely limited transgene
expression in macrophages, but had little or no effect in other cell types tested.  This
decreased transfection was dependent on ROS-mediated cellular toxicity induced by
endotoxin. Our results indicate that multiple oxidative species are involved in the
transfection inactivation process, and that .OH radicals, formed by H2O2–dependent,
metal-catalyzed Fenton reaction, play a major role in this process.
4. IL-10 inactivates macrophage production of reactive oxygen radicals, thereby
decreasing inflammation. Specifically, we propose that IL-10 inhibits ROS production
which in turn inhibits IKK activity and hence, IκBα degradation.  This results in a
decrease in NF-κB activity and hence, decreases the expression of inflammatory
cytokines such as TNFα.  This whole cascade of events is responsible for the anti-
inflammatory properties of IL-10 in macrophages.
5. ROS play a key role in cationic lipid-mediated toxicity. The charge of a liposome is a
key determinant of toxicity. Cationic liposomes cause inflammation and toxicity via a
pathway that involves the generation of oxygen free radicals because scavenging
these radicals decreases toxicity. Polyvalent cationic liposomes are more toxic than
their monovalent counterparts.
6. IL-10 gene transfer can downregulate mouse lung inflammation and cell activation in
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